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Abstract 
Vascular disease is a common cause of death that typically results from 
long-term alteration of vessel structure and function. The underlying mechanisms 
that lead to pathologic changes in the vasculature are largely unclear, especially 
in progressive diseases of the cerebral vessels. With the growing prevelance of 
blast traumatic brain injury in modern warfare, never before has investigation of 
cerebral vascular disease been more pertinent. Here, we focus on the 
development of microfabrication experimental approaches for probing the critical 
mechanical and biochemical pathways involved in progression of diseases, such 
as cerebral vasospasm, subarachnoid hemorrhage, and Alzheimer’s disease, that 
often result from TBI.    
First, we develop a microfluidic patterned deposition technique for studying 
functional mechanics in chronic vascular disease at the tissue scale. We modify 
substrate surfaces with genipin, a natural crosslinker, to extend culture times of in 
vitro vascular tissues that mimic native tissue structure and function. We 
successfully validate our technique, showing maintenance of patterned structural 
alignment and mechanical function over the course of two weeks. 
Lastly, we investigate the relationship between vascular disease and 
Alzheimer’s disease. Amyloid beta is a key precursor in the development of 
Alzheimer’s disease that accumulates in neuronal and cerebrovascular tissue and 
can result in neurodegeneration. During the development of cerebral amyloid 
angiopathy (CAA), which is present in over 80% of Alzheimer's disease cases, 
amyloid beta plaques form in the cerebral vessel walls and lead to severe 
attenuation of physiologic vasodilation. We measured the effect of amyloid beta 
treatment on vascular smooth muscle cell functional contractility using a single-cell 
traction force microscopy technique and developed a thin-walled arterial model for 
growth and remodeling response to mechanical perturbations. We found that 
amyloid beta induces a reduction in vascular smooth muscle cell mechanical 
output. We implemented this loss of function into a constrained mixture arterial 
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model that suggests vessel growth and remodeling, in response to amyloid beta-
mediated alteration of smooth muscle function, can lead to an inability of cerebral 
vessels to vasodilate. Our findings provide a possible explanation for the vascular 
injury and malfunction often associated with the development of 
neurodegeneration in Alzheimer’s disease. 
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Chapter 1. Introduction 
Vascular disease is a broad canopy under which a wide variety of disease 
mechanisms, afflicted areas of the human body, and complications reside. Given 
the continuous flow of blood and importance of its delivery of nutrients and oxygen 
to all tissues of the body, disruptions in vascular function can have devastating 
consequences. This is especially true in the cerebral vasculature, due to the limited 
regenerative capacity of brain tissue. With the advent of improved armor, modern 
warfare has led to a striking increase in blast traumatic brain injuries [1]. Soldiers 
who typically died in past wars are now surviving, yet sustaining invisible injuries 
that manifest themselves in lost brain function over time. The nature of these injury 
mechanisms can be difficult to isolate, due to the closely-knit interaction between 
the cerebral vasculature and neural networks of the brain [2]. Our goal is to develop 
techniques to allow investigation of the underlying mechanisms that can result in 
the wide array of downstream progressive diseases that manifest themselves after 
exposure to blast trauma.  
Cerebral arteries, like most tissues, exist as a complex structure composed 
mainly of cells and extracellular matrix. The unique metabolic loads of brain tissue 
require cerebral arteries to be highly dynamic in nature [3]. Arteries contract or 
relax to modify blood flow rates and maintain fluid shear stress [4], a direct 
correlate to the activity of the tissues to which they deliver blood containing oxygen 
and nutrients. Thus, the mechanical function of arteries is paramount to the 
function of the surrounding tissue as a whole. The main contractile component of 
arteries is the vascular smooth muscle cells (VSMCs), which typically exist in 
concentric sheets of circumferentially-aligned cells alternating with layers of 
collagen and elastin in the media layer of arteries [5]. The mechanical function of 
these cells tends to become perturbed in development of vascular disease. A 
common theory in vascular function, growth and remodeling theory, suggests that 
vascular smooth muscle has an ideal stress level which, when perturbed away 
from, the smooth muscle adapts to return to this so-called target stress [6]. This 
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mechano-adaptation can occur via proliferation or hypertrophy of VSMCs [7, 8] or 
changes in the active contractile force exerted by the cells within the arterial wall 
[9]. A method to capture the mechano-adaptive behavior of VSMCs is highly-
desirable, as this behavior is often a hallmark of disease progression. 
The role of mechanics in VSMC function has been extensively studied. 
Several experimental techniques can be employed to determine mechanical 
properties of VSMCs, in addition to direct mechanical stimulation of cells [10]. 
Mann et al. utilized a flexible micropost array and employed vacuum pressure to 
apply stretch directly to VSMCs [11]. Traction force microscopy (TFM) has been 
used extensively to assess a wide variety of cell types and their mechanical output 
in highly-controlled experimental conditions, both in 2-D and 3-D culture [12-14]. 
However, TFM does not allow for tissue-level assessment of vascular mechanical 
function. Vascular muscular thin films have been employed to measure stress in a 
monolayer of highly-aligned, confluence sheets of VSMCs designed to mimic the 
in vivo tissue structure [15].  
To investigate the role of vascular mechanics in progressive diseases, we 
have developed a two-pronged approach. Our first aim is to develop an improved 
technique for probing vascular mechanics over disease-relevant time courses and 
in a relatively high-throughput manner. Second, we invoke existing techniques to 
investigate specific pathological effects on vascular mechanics in a highly-
controlled in vitro assay. The primary motivation for both aims is the induction of 
vascular injury that occurs in blast traumatic injury. We investigate the literature 
findings in depth to frame the many diseases that may arise (Chapter 2). To 
provide a more relevant system for assessing the chronic nature of most vascular 
diseases, we develop a microfluidic deposition technique for crosslinking 
extracellular matrix to PDMS substrates previously used in vascular muscular thin 
films (Chapter 3) [15].  
Next, we attempt to elucidate the effects of blood-borne factors that are 
released and shown to have higher concentrations in the blood and cerebral spinal 
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fluid after subarachnoid hemorrhage that often occurs with TBI (Chapter 4). These 
factors are thought to contribute to the development of cerebral vasospasm (CVS), 
which is a mechanically-characterized vascular disease with acute hyper-
contractility, followed by prolonged arterial remodeling that leads to further 
occlusion of cerebral arteries. CVS is an example of the maladaptive outcomes 
that often arise from the arterial growth and remodeling response.  
Lastly, we turn toward Alzheimer’s disease, which has many connections to 
vascular disease, especially considering the common progression with 
presentation of cerebral amyloid angiopathy (CAA) in which amyloid beta deposits 
become prevalent in the cerebral vessel walls [16, 17]. The so-called amyloid 
hypothesis implicates amyloid beta in Alzheimer’s disease progression, but it is 
largely disputed as to how amyloid beta leads to neurodegeneration. We 
investigate the functional mechanics of VSMCs when exposed to amyloid beta to 
determine if vascular mechanics may play a critical role (Chapter 5).  
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Chapter 2. Smooth Muscle Phenotype Switching in Blast 
Traumatic Brain Injury-Induced Cerebral Vasospasm 
 
This chapter contains material from an invited review article previously published 
in Translational Stroke Research and is reproduced with permission. Hald ES and 
Alford PW. Smooth Muscle Phenotype Switching in Blast Traumatic Brain Injury-
Induced Cerebral Vasospasm [18]. 
 
2.1  Summary 
Due to increased survival rates among soldiers exposed to explosive blasts, 
blast traumatic brain injury (bTBI) has become much more prevalent in recent 
years. Cerebral vasospasm (CVS) is a common manifestation of brain injury 
whose incidence is significantly increased in bTBI. CVS is characterized by initial 
vascular smooth muscle cell (VSMC) hypercontractility, followed by prolonged 
vessel remodeling and lumen occlusion, and is traditionally associated with 
subarachnoid hemorrhage (SAH). But, recent results suggest that mechanical 
injury during bTBI can cause mechanotransduced VSMC hypercontractility and 
phenotype switching necessary for CVS development, even in the absence of 
SAH. Here, we review the mechanisms by which mechanical stimulation and SAH 
can synergistically drive CVS progression, complicating treatment options in bTBI 
patients. 
 
2.2 Introduction 
Traumatic brain injury (TBI) affects as many as 1.7 million people in the 
United States each year [19]. Most TBIs are caused by blunt force blows to the 
head, but more rarely, bTBI can occur following exposure to an explosive blast 
wave. Due to the increased use of improvised explosive devices, along with 
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improved survival rates, soldiers returning from Iraq and Afghanistan suffer a 
higher prevalence of bTBI than those of previous wars [1, 20, 21]. Thus, it is 
important to determine the mechanisms of bTBI and subsequent 
neurodegeneration, which may vary from those of more common TBI injuries. 
CVS is a secondary manifestation of TBI whose incidence is increased in 
bTBI, compared to other forms of TBI [22, 23]. CVS is characterized by acute 
vascular hypercontraction followed by chronic cell proliferation and extracellular 
matrix remodeling, typically resulting in delayed ischemia [24-26]. For chronic CVS 
to occur, VSMCs in cerebral arteries must undergo phenotypic switching from a 
contractile to a synthetic phenotype [26, 27]. Both SAH [26] and mechanical 
stimulation [27] can induce phenotypic transformation necessary to prolong CVS. 
These competing stimuli provide a complex signaling milieu that may lead to 
increased incidence and earlier onset of CVS in bTBI patients. Here, we review 
recent findings in the area of cerebral vascular mechanics associated with TBI and 
vascular injury, via modulation of VSMC phenotype. We then discuss some recent 
developments in clinical treatments of TBI-induced cerebral vasospasm that may 
be specifically of interest for bTBI patient treatment.  
 
2.3 Acute Vascular Injury in TBI  
The pathways of bTBI injury are not currently fully understood, but direct 
mechanical insult by the transient pressure wave produced by an explosive device 
clearly plays some role in injury progression. The blast shock wave produces 
localized particle motion in the tissues it passes through, possibly transducing 
injury seen in bTBI. The injury may be caused by the wave passing directly through 
the skull or transmitting through soft tissue from other locations in the body. One 
provocative hypothesis is that kinetic energy from the blast may enter the body in 
the abdomen or chest and propagate through large blood vessels to the cerebral 
vasculature [28] (Fig. 2.1, center). Both rat and swine models exposed to blasts 
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support this hypothesis, suggesting direct interaction between the head and blast 
wave and vascular fluid transfer of injury synergistically contribute to bTBI [29, 30]. 
Blast propagation through the vasculature suggests a greater role for vascular 
mechanical stimulation in bTBI-induced CVS than in non-blast blunt-force TBI (Fig. 
2.2).  
Even small changes in mechanical environment can affect cellular function, 
so unsurprisingly the extreme forces associated with bTBI dramatically affect cells 
in the neurovascular unit (NVU), which is composed of vascular cells, glial cells, 
and neurons [31]. In neurons, large strains can induce membrane poration, 
causing increased intracellular calcium (Ca2+) levels that lead to calponin 
upregulation and axonal collapse [32-34]. Small strains at high strain rates can 
also induce neuronal focal swelling through a similar Ca2+-mediated pathway, 
suggesting integrin stimulation may also play a critical role in acute neuronal injury 
in TBI [35].  
Blast wave-induced injury in cerebral arteries affects the vessels’ acute 
mechanical function. Primary blast waves in the cerebrovasculature can cause 
small, focal lesions in the vessels that are distinct from those produced in studies 
of other forms of TBI [36]. In VSMCs, high-velocity strains can increase intracellular 
Ca2+ levels in vitro, resulting in acute hypercontractility, suggesting that that blast 
alone can elicit an early-stage vasospastic response in VSMCs [27]. 
Forces applied to cerebral arteries during bTBI via volumetric blood surge 
can lead to microvessel injury or disruption of the NVU’s blood-brain barrier (BBB) 
[36-41], a layer of endothelial cells that limits the entry of harmful blood cells and 
plasma constituents into the brain tissue [31] (Fig 2.1, center). The resulting SAH, 
or bleeding in the subarachnoid space, exposes the NVU to whole blood and can 
cause a range of dysfunction due to induced activation of astrocytes and microglia 
[42]. In addition, SAH leads to secondary development of CVS. The classical view 
of SAH-induced CVS suggests that activated platelets in SAH-related 
extravascular clots are responsible for producing a wide variety of proteins that 
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promote contraction of the injured blood vessel [26], limiting blood loss, and growth 
of new vascular tissue, accelerating repair [43]. Hemoglobin, found in SAH blood, 
scavenges the endothelium-produced vasodilator nitric oxide (NO), limiting NO’s 
relaxation effect on VSMCs [44-46]. In addition, common SAH-associated 
vasoconstrictors, including serotonin [47], thromboxane [48], thrombin [48], and 
endothelin-1 (ET-1) [48-50], may play a role in SAH-CVS progression by inducing 
increased intracellular calcium and thus, hypercontractility [51], similar to that seen 
due to mechanical stimulation [27].  
Additionally, TBI has been shown to activate endothelial cells [52], and SAH 
often results in endothelial injury [53], which can affect the ability of cerebral 
vasculature to adapt to the pathological environment immediately following a TBI. 
For example, many of the factors released in SAH have been shown to increase 
synthesis and release of the vasoconstrictor ET-1 by endothelial cells [54] possibly 
initiating CVS [55]. In addition to this increased ET-1 production, recent results 
suggest ET-receptors in VSMCs are also affected in CVS. Two subtypes of ET 
receptors, ET(A) and ET(B), modulate mechanical pathways in VSMCs and 
endothelial cells. ET(A)-receptor is prevalent in VSMCs and mediates the 
contractile effects associated with CVS. ET(B)-receptor is responsible for 
vasorelaxation via stimulation of NO-synthase and downstream NO release from 
endothelial cells. The ET(B)-receptor signaling cascade is lost in CVS, though the 
mechanism is not clear [56]. 
Shortly following bTBI injury, the VSMCs’ mechanical function is 
significantly perturbed. VSMCs are more inherently contractile, while being 
simultaneously stimulated with elevated vasoconstrictor signaling from the 
endothelium and extravascular SAH. The resulting hypercontractility increases the 
stress borne by the VSMCs and causes the vessel lumen to narrow. This 
hypercontractility by itself is reversible. However, when coupled with vessel 
remodeling, which can be occur in response to both mechanical stimulation and 
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SAH, prolonged narrowing of the lumen can occur, leading to the serious 
pathologies associated with CVS [26].  
 
2.4 Phenotype Switching and Chronic Vascular Injury in TBI 
VSMCs express two distinct phenotypes: contractile and synthetic. Healthy 
homeostatic vessels are predominantly populated with contractile VSMCs, which 
produce greater contractile forces and minimally migrate, proliferate, or remodel 
surrounding extracellular matrix (ECM). Synthetic VSMCs, characterized by 
increased migration, proliferation, and remodeling as well as decreased 
contractility, are often present in injured vessels [57]. Thus, large-scale remodeling 
necessary for CVS progression requires phenotypic switching in VSMCs [58, 59]. 
Among the stimuli that can induce phenotype switching in VSMCs are mechanical 
stimulation [27, 60, 61] and a number of clot-related factors present in SAH [25, 
26, 48-50, 62-67]. Given the extreme mechanical loads and presence of SAH in 
bTBI [23], the elevated incidence of CVS in bTBI suggests a possible synergistic 
mechanism between mechanotransduced and SAH-induced CVS may be at work.  
 
2.5 Mechanics and VSMC Phenotype 
A long-standing theory in biomechanics posits that tissues maintain a 
homeostatic preferred stress and that perturbations in their mechanics induce 
them to remodel to return their stress to this preferred value [68]. An example of 
this mechanism is thickening and stiffening of arteries in hypertension [6, 69-73]. 
For this remodeling to occur, mechanics must modulate VSMC function. Many 
studies have shown a complex milieu of mechanical effects on phenotype 
behavior, suggesting a mixture of VSMC phenotype in arterial walls undergoing 
pathological strains. In vivo hypertensive arteries show increased expression of 
matrix metalloproteinases (MMPs), consistent with a switch toward a synthetic 
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population [74, 75]. Conversely, serum response factor (SRF) and myocardin are 
prevalent transcription factors upregulated in hypertension and CVS, as their 
overexpression produces the contractile VSMC phenotype [76]. In vitro cyclic 
strains induce both contractile [77, 78] and synthetic [79, 80] shifting, depending 
on the experimental conditions. Large strains have been shown to result in VSMC 
behavior often associated with the synthetic phenotype, such as hypertrophy and 
increased matrix synthesis [81]. VSMCs have also been shown to modulate their 
phenotype in response to changes in substrate mechanics [82], with higher ECM 
stiffness inducing increased cell-substrate interaction and increased synthetic 
phenotype expression [83]. Furthermore, changes in ECM mechanics affect cell 
morphology [84] and motility [85], which can correlate with phenotype 
transformation.  Taken together, these data suggest that phenotype switching 
plays an important role in tissue stress maintenance. 
A population study of bTBI patients found that post-traumatic vasospasm 
can occur secondary to primary blast alone, suggesting that mechanotransduced 
CVS can occur independent of SAH in bTBI [86]. This observation is supported by 
in vitro results wherein vascular tissues exposed to blast-like stretch showed 
differences in functional contractility and phenotype expression, depending on the 
severity of the stretch, one day post-blast injury [27]. Mild injury induced 
hypersensitivity to ET-1 stimulation, while severe injury decreased response to ET-
1. Consistent with these results, key contractile phenotype markers were down-
regulated in the severe injury, suggesting that mechanical injury alone could drive 
phenotype switching necessary to prolong CVS. Notably, inhibition of tissue 
hypercontractility with a rho kinase inhibitor reduced phenotype switching following 
blast-like stretch [27]. Considering acute injury, hypercontractility, hypertension, 
and hypotension [87], which occur after blast, mechanically-induced growth and 
remodeling likely play a role in the progression of CVS after blast injury. 
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2.6 SAH and VSMC Phenotype 
While CVS can occur in bTBI in the absence of SAH, normally SAH is 
present, so its contribution must also be considered. SAH-borne factors can 
modulate VSMC behavior via a variety of signaling cascades that shift VSMC 
phenotype. These pathways are quite complex, complicating determination of 
exactly how SAH leads to CVS.   
Mitogens, such as transforming growth factor beta (TGF-β), platelet-derived 
growth factor (PDGF) [74, 75], and ET-1 [88] (which can act as either a mitogen or 
a vasoconstrictor) promote VSMC proliferation and modulate VSMC phenotype. 
TGF-β induces expression of cytoskeletal genes associated with the VSMC 
contractile phenotype [89]. This switching occurs at least 16 hours post-exposure, 
consistent with delayed SAH-associated hypercontractility in CVS. TGF-β-induced 
increased expression of these genes coincides with that of cysteine and glycine-
rich protein 2 (CSRP2), a smooth muscle cell-restricted signaling molecule. This 
increase in CSRP2 is counter to the severe downregulation of CSRP2 typically 
seen when SMC proliferation is increased [90], further suggesting TGF-β acts to 
shift SMCs toward the contractile phenotype. TGF-β also directly upregulates 
CSRP2 in VSMCs by activating transcription factor 2 [91]. Thus, the pathologic 
exposure of SMCs to TGF-β, a common component of whole blood, could 
contribute to increased contractility via a phenotype transformation. In contrast, 
PDGF stimulates downregulation of SMC contractile markers, such as smooth 
muscle myosin heavy chain (SM-MHC) and smooth muscle α-actin (SM-α), 
indicating a switch from contractile to synthetic phenotype [92-94]. Additionally, 
MT1-MMP, an enzyme responsible for degradation of ECM proteins, in conjunction 
with PDGF, contributes to the VSMC synthetic phenotype, as MT1-MMP deficiency 
results in decreased VSMC remodeling [95]. Further work elucidating the exact 
mechanism or mechanisms by which PDGF modulates transcription and SMC 
phenotype has been extensively reviewed [59]. 
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Activation of store-operated Ca2+ channels (SOCC) is also associated with 
occurrence of CVS in a SAH rat model [96]. This activation occurs as a result of 
ET-1 stimulation, which is heightened in SAH. Various studies have also implicated 
SOCC in VSMC phenotype transformation, as VSMCs’ contractile-to-synthetic 
switching is greatly increased by store-operated Ca2+ entry [97, 98]. Considering 
these findings, the complex role of ET-1 in both hypercontractility and VSMC 
phenotype switch from contractile to synthetic and its relation to calcium handling 
suggest the significant importance of ET-1 in SAH-associated CVS. 
Both hypoxia and direct endothelial damage due to SAH upregulate MMP-
9 and vascular endothelial growth factor (VEGF), and induce increased VSMC 
proliferation [65]. Studies in adult sheep arteries found reduced levels of contractile 
phenotype marker SM-MHC colocalized to SM-α in hypoxic conditions as 
compared to normoxic, suggesting hypoxia plays a role in phenotypic 
transformation leading to vascular remodeling [99]. In fetal arteries, in addition to 
VEGF itself, hypoxia can also directly increase expression of VEGF receptors 
[100]. This has a similar effect on contractile phenotypic markers, suggesting the 
importance of VEGF and its receptors in a positive feedback mechanism 
influencing VSMC phenotype transformation and cerebral vascular remodeling 
that is associated with CVS and hypoxia.    
  
2.7 Mechanico-Chemical Synergy in bTBI-induced CVS 
Computational modeling provides insight into the possible synergy of 
mechanical and SAH pathways in bTBI-induced CVS. Clinically, bTBI accelerates 
CVS onset relative to SAH [23]. Mechanically-induced CVS can be initiated as 
soon as 24 hours post-injury in vitro [27], whereas SAH-induced CVS typically 
occurs over 3-7 days [101]. These temporal differences could play a key role in the 
mechanico-chemical synergy in CVS progression proposed by Humphrey et al.  
[26]. In this theory, several remodeling steps occur in response to hypercontractility 
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present in the early stages of CVS, which initially intensify hypercontractility, but 
eventually aide in returning the artery to a desired stress state. SAH clot-related 
mitogens, such as PDGF and TGF-β, promote VSMC proliferation and migration 
[24], causing a shift in the active force-length curve and leading to further tissue 
remodeling. Maladaptive vessel wall thickening and stiffening, which serve as a 
long-term means for returning the vessel to its normal state [6, 69-73], occur but 
are initially superseded by the shift in the force-length curve [26]. Flow dynamics, 
along with the altered mechanics of the remodeled vessel, continue to induce cell 
and matrix remodeling, eventually returning the vessel to its normal dimensions 
and stress state [26]. Computational modeling also predicts the importance of 
phenotypic switching in mechanotransduced CVS progression in bTBI, suggesting 
that VSMCs in CVS exhibit mixed populations of hypercontractile and synthetic 
cells [27]. Taken together, this work suggests that mechanical growth and 
remodeling theory can be used to better understand the gross mechanisms of 
bTBI-induced CVS progression. 
 
2.8 Clinical Treatment of Vascular Injuries Associated with TBI 
Treatments for CVS can target either short-term hypercontractility or long-
term remodeling.  Proposed treatments of CVS-associated sustained VSMC 
contraction have primarily targeted the Rho/Rho-kinase pathway. Pharmaceutical 
targeting of single proteins in the pathway, such as RhoA with statin or Rho-kinase 
with fasudil, has proven insufficient in attenuating CVS after SAH [102, 103]. 
Recent combination therapy using pitavastatin and fasudil showed increased 
attenuation of CVS in rabbit arteries, suggesting similar synergistic targeting of the 
Rho/Rho-kinase pathway may prove beneficial in combating CVS 
hypercontractility [104]. Direct targeting of calcium channels via calcium channel 
blockers, such as nicardipine [105, 106] and nimodipine [107], has also been 
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employed in the treatment CVS, though general outcomes do not necessarily 
improve as a result of such treatment.  
TBI proteomics provides another significant research area of interest, both 
in pharmaceutical treatment of TBI and in cross-referencing with the biochemical 
pathways initiated by SAH [108]. A review of TBI mechanisms and current 
diagnostic methods found that a panel of biomarkers associated with damaged 
neurons and/or astrocytes  shows the greatest promise for determining the type 
and level of TBI experienced by patients [109]. The high sensitivity and acute 
presence in the blood post-injury of these biomarkers make them a suitable target 
for expedited diagnosis via field diagnostic biosensors [109]. This is of particular 
interest for TBIs sustained on the battlefield.  
Recent proposed gene therapies have also shown promise in attenuating 
CVS in SAH. For example, heme-oxygenase-1 (HO-1) is critical in heme 
catabolism, which can reduce the contractile effect of hemoglobin after SAH. 
Recently, transduction of HO-1 fused with a common protein transduction domain 
sequence of 11 consecutive arginine residues allowed integration of the fused 
protein into the membranes of arterial cells, significantly attenuating CVS after 
SAH [110]. Magnesium sulfate provides another alternative treatment for 
combating CVS hypercontractility and its pathological effects downstream of SAH. 
Magnesium sulfate blocks the release of amino acids that promote 
hypercontractility downstream of initial SAH, and acts as a direct vasodilator, 
maintaining cerebral blood flow in a physiologically-suitable range for maintaining 
tissue homeostasis [111]. Magnesium sulfate treatment has been shown to 
improve outcomes in SAH patients via reduction of delayed ischemia [112].  
Specific factors and pathways associated with SAH have been targeted for 
therapeutic treatment of SAH-induced CVS. Treatment of CVS with ET-1 
antagonists, such as clazosentan, has proven effective, further elucidating the 
critical role of ET-1 in CVS development and progression [113]. However, 
Clazosentan to Overcome Neurological Ischemia and Infarct Occuring after 
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Subarachnoid Hemorrhage (CONSCIOUS) clinical trials have not shown improved 
SAH outcome [114-116]. Treatment with a phosphodiesterase type III inhibitor, 
cilostazol, resulted in attenuation of vasospastic effects in concert with prevention 
of phenotype transformation [117], suggesting that SAH-induced CVS is 
maintained via phenotype switching. Hyperbaric oxygen treatment has also been 
shown to limit the damage to neural tissue caused by SAH-induced CVS [118]. 
Recent work has further elucidated a possible mechanism for this attenuation via 
decreased expression of hypoxia-inducible factor-1α and downstream inhibition of 
matrix MMPs [119] responsible for cleaving ECM proteins and tight junctions 
connecting endothelial cells. Downregulation reduces this effect, limiting BBB 
disruption and reducing damage to neural tissue. MMP inhibition has also been 
found to constrain rapid changes in vessel mechanical properties due to changes 
in flow dynamics and mechanical stimulation in carotid arteries [120, 121]. A similar 
mechanism may be at play in the cerebral vasculature, as MMPs have also been 
implicated in VSMC phenotype transformation. To date, no singular treatment has 
shown the ability to unilaterally attenuate the effects of CVS.  
 
2.9 Alternative Pathomechanisms in bTBI 
While CVS can directly lead to patient mortality, it is unclear whether it plays 
a primary role in long-term bTBI outcome in survivors. Reviews of clinical 
vasospasm treatment have shown limited improvement in patient outcome [122]. 
Ischemia can lead to cerebral infarction in TBI and CVS patients, but recent work 
suggests that the importance of CVS in delayed ischemia is limited [122-125]. 
Cerebral infarction, conversely, can have a direct negative effect on clinical 
outcomes, independent of vasospasm [125] and is a better determinant of outcome 
than CVS [124]. Cortical spreading ischemia follows SAH and contributes directly 
to focal necrosis of brain tissue [123]. In addition, other pathomechanisms may 
play significant roles in bTBI patient outcome, rendering treatment of CVS less 
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effective. Blast forces can directly injure neural tissue via metabolic disturbances 
[126, 127] and astroglial-induced neuronal swelling [128]. Activation of the 
neuroendocrine-immune system due to post blast injury release of autacoids into 
the blood also directly contributes to induction of secondary brain injury [129].  
Further work is needed to fully elucidate the relative contributions of different 
pathomechanisms to secondary brain injury in bTBI and determine the best course 
of treatment to prevent and combat severe complications that result from bTBI. 
 
2.10 Conclusion 
With the rising incidence of bTBI worldwide, it is imperative to better 
understand the injury mechanisms that drive its progression. Due to the unique 
mechanical loading on cerebral vasculature during blast injury, mechanisms of 
bTBI-induced CVS likely vary from those of more traditional CVS cases, likely 
accounting for the increased incidence of CVS in bTBI patients. Further exploration 
of the synergistic influence of mechanics and SAH in VSMC phenotype switching 
in CVS is vital for developing appropriate treatment strategies for future bTBI 
patients. 
  
 16 
 
 
Figure 2.1. Acute injury of vasculature due blast injury. 
Blast pressure waves propagate through the healthy vessel, resulting in 
mechanical VSMC stimulation and, in severe cases, vessel rupture and 
subsequent SAH. Clotting factors released from the SAH clot result in acute 
hypercontractility and remodeling consistent with CVS progression. 
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Figure 2.2. Schematic of complex milieu of mechanical and biochemical 
pathways linked to VSMC phenotype transformation as a result of bTBI. 
Acute mechanisms are in blue at top, chronic mechanisms/effects are in red at 
bottom. 
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Chapter 3. Microfluidic Genipin Deposition Technique for 
Extended Culture of Vascular Muscular Thin Film Contractility 
Assays 
 
This chapter contains material previously published in Biofabrication and is 
reproduced with permission. Hald ES, Steucke KE, Reeves JA, Win Z, and Alford 
PW (2014) Long-Term Vascular Contractility Assay Using Genipin-Modified 
Muscular Thin Films [130]. © IOP Publishing.  Reproduced with permission.  All 
rights reserved. 
 
3.1 Summary 
Vascular disease is a leading cause of death globally and typically 
manifests chronically due to long-term maladaptive arterial growth and remodeling. 
To date, there is no in vitro technique for studying vascular function over relevant 
disease time courses that both mimics in vivo-like tissue structure and provides a 
simple readout of tissue stress. We aimed to extend tissue viability in our muscular 
thin film contractility assay by modifying the polydimethylsiloxane (PDMS) 
substrate with micropatterned genipin, allowing extracellular matrix turnover 
without cell loss. To achieve this, we developed a microfluidic delivery system to 
pattern genipin and extracellular matrix proteins on PDMS prior to cell seeding. 
Tissues constructed using this method showed improved viability and 
maintenance of in vivo-like lamellar structure. Functional contractility of tissues 
fabricated on genipin-modified substrates remained consistent throughout two 
weeks in culture. These results suggest that muscular thin films with genipin-
modified PDMS substrates are a viable method for conducting functional studies 
of arterial growth and remodeling in vascular diseases. 
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3.2 Introduction 
Cardiovascular disease accounts for an estimated 17.3 million deaths 
annually and is the leading cause of death globally [131]. Vascular diseases are 
rarely acute dysfunctions, but are instead slow-developing and often chronic. For 
example, cerebral vasospasm is typically diagnosed 3-7 days posttrauma [18, 132] 
and can persist for up to two weeks [133]. Atherosclerosis and aneurysms can 
develop for years prior to clinical complications [134, 135]. One hallmark of these 
diseases is the pathologic perturbation of vascular smooth muscle cell (VSMC) 
function. In the complex milieu of an in vivo artery, it is often difficult to isolate 
pathways that lead to VSMC dysfunction. Thus, it is desirable to develop in vitro 
methods with more highly-controlled experimental conditions. To date, an in vitro 
model that can explore vascular function over physiologically-relevant time scales 
of vascular pathologies does not exist.  
The need to isolate underlying pathological mechanisms has long driven 
researchers toward development of reductionist in vitro methods, but with the 
consequence of lost functional integrity and system-level complexity. But, recent 
advances in organ-on-a-chip technologies have revolutionized the way 
researchers develop in vitro models for pathophysiological investigation by 
employing microfabrication and microfluidic techniques to control flow dynamics 
and temporospatial microenvironments [136, 137]. To date, liver-, kidney-, lung-, 
and heart-on-a-chip systems, which more closely mimic the tissue-level chemical, 
mechanical, and electrophysiological environments of in vivo organ systems, have 
shown great promise as pharmaceutical screening assays [138-141]. Arteries-on-
a-chip that mimic the endothelium-blood interaction within the arterial lumen [142] 
and simulate physiologic blood flows [143] have been developed as well. An artery-
on-a-chip that could simply measure VSMC function over pathophysiological time 
courses would provide an ideal platform for studying pathways and treatments for 
slower-developing vascular disorders.  
 20 
 
Previously, we developed a method for measuring VSMC function called 
vascular muscular thin films (MTFs) that can be implemented into an artery-on-a-
chip platform. The MTF is a two-layer biohybrid construct consisting of a monolayer 
of VSMCs patterned via microcontact printing (µCP) [144] of extracellular matrix 
(ECM) onto a PDMS substrate [15, 145]. Stress in the cell layer due to muscle 
contraction, the key measure of vascular muscle function, causes the construct to 
bend. This stress can then be calculated using the radius of curvature and known 
mechanical properties of the MTF layers. MTF technology has proven useful in 
studying acute mechanical and biochemical dynamics of arteries [145], as well as 
cardiomyocytes [15] and valve endothelial cells [146]. However, we observed that 
vascular tissue integrity decreased rapidly starting four days after seeding on these 
constructs. This decrease in cellular attachment is likely due to the combination of 
hydrophobic recovery of PDMS [147] and enzymatic degradation of ECM [148] that 
results in delamination of tissues. Thus, for MTFs to be a robust method for 
studying vascular pathogenesis, a new method for constructing tissues with 
extended viability is necessary. 
Most cells, including VSMCs, will not adhere to unmodified PDMS. Several 
surface modification techniques have been proposed to effectively ‘mask’ 
biological materials from the hydrophobicity of PDMS [149-152]. However, 
following these treatments, cells are rarely viable past one week. Recently, surface 
modification of PDMS with genipin, a commonly used crosslinking protein, has 
shown promise in prolonging viable culture of myoblasts [153]. Genipin features 
low toxicity compared to other common biological crosslinking agents and high 
versatility as a biomaterial with numerous applications in tissue repair [154-156] 
and ECM modification [157-159].  
Here, we present a method for measuring vascular smooth muscle 
contractility over physiologically-relevant time scales. We modified our previous 
MTF method by micropatterning the PDMS layer with genipin to allow longer 
culture times, while maintaining tissue structure. We also assessed temporal 
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changes in tissue structure and contractile function of vascular tissues constructed 
on genipin-modified PDMS surfaces and compared to those fabricated using µCP. 
We found that tissues show improved viability on genipin-modified surfaces and 
maintain consistent basal tone with decreased responsiveness to endothelin-1-
induced contraction over the course of 14 days. This method provides the 
framework for future investigations of pathological VSMC function in slow-
developing vascular diseases.   
 
3.3 Materials and Methods 
3.3.1 Tissue Fabrication and Characterization 
All tissues were fabricated on Sylgard 184 (Dow Corning) PDMS substrates. 
PDMS was spin coated on a 25-mm diameter glass cover slip and cured at 65 °C 
for 4 h. Two methods, microcontact printing (µCP) and microfluidic delivery were 
used to pattern micro-scale guidance cues for tissue organization onto PDMS 
substrates.  
 
3.3.1.1 Microcontact Printing 
Stamps with microscale features were fabricated using traditional 
photolithographic techniques. Briefly, photomask films were designed with 
alternating lines of 10-µm width with 10-µm pitch between (Fig. 3.1 A, top). The 
photomasks were used to selectively expose SU-8 photoresist (MicroChem) spin 
coated onto silicon wafers with a feature height of 5 µm. Stamps were fabricated 
by pouring PDMS onto respective patterned silicon wafers. After degassing, PDMS 
was cured at 65 °C for 4 h. Stamps were then cut into appropriate shapes for use 
in tissue fabrication. µCP was used to pattern fibronectin (FN) onto PDMS 
substrates. FN (BD Biosciences) at 50 µg/ml concentration was incubated on 
patterned PDMS stamps for 1 h at room temperature (Fig. 3.1 A). FN was 
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transferred to PDMS-coated cover slips after UVO surface treatment, yielding high-
fidelity lines of FN on the PDMS substrates (Fig. 3.1 A). Samples were rinsed in 
1X PBS (Corning) prior to seeding. 
 
3.3.1.2 Microfluidic Protein Delivery 
Microfluidic devices were fabricated using the same methods as µCP 
stamps, but using a modified photomask film with branching channels and SU-8 
photoresist with 20-µm feature height. Starting as a single channel, the pattern 
branched in a binary fashion until channels of 10-µm width were separated by walls 
of 10-µm width, yielding the same pattern as µCP stamps (Fig. 3.1 A, bottom). Inlet 
and outlet vertical channels were made using a 1-mm biopsy punch. After UVO 
surface treatment, devices were sealed onto PDMS-coated cover slips via 
conformal contact. Devices were primed with 70% ethanol, then rinsed with 1X 
PBS. Microfluidic protein delivery was used to deposit either FN only or to serially 
deposit genipin and FN (Gen+FN). To deliver FN only, 100 µl of 50 µg/ml FN was 
placed at the inlet and drawn through via negative pressure. FN was incubated at 
37 °C for 24 h. To deliver Gen+FN, genipin (Cayman Chemical) was resuspended 
in sterile ddH2O at a concentration of 1 mg/ml. 50 µl of genipin solution was placed 
at the inlet and drawn through the device slowly using a house vacuum (Fig. 3.1 
A, bottom). Drops of 1X PBS were placed at both inlet and outlet to maintain 
wetting while genipin was incubated at 37 °C for 4 h. After incubation, 1X PBS was 
drawn through the device to remove excess genipin. Next, 100 µl of 50 µg/ml FN 
was placed at the inlet and drawn through the device slowly via negative pressure. 
FN was incubated at 37 °C for 24 h. After FN incubation, devices were carefully 
peeled away, and cover slips were rinsed in 1X PBS prior to seeding.  
 
 
 
 23 
 
3.3.1.3 Vascular Smooth Muscle Cell Culture and Seeding 
Human umbilical artery vascular smooth muscle cells (VSMCs) were 
purchased at passage 3 from Lonza and cultured in growth medium containing 
M199 medium with 10% FBS, 50 U/ml penicillin, 50 U/ml streptomycin, 10 mM 
HEPES, 1X MEM Non-Essential Amino Acids, 2 mM L-glutamine, 3.5 g/L glucose, 
and 2 mg/L Vitamin B12 supplement. Passages 5-7 were used for seeding 
constructs coated in FN (Fig. 3.1 B). µCP substrates were seeded at 65,000 
VSMCs/cm2. All microfluidic patterned substrates were seeded at 80,000 
VSMCs/cm2 to ensure confluent tissues. Higher cell seeding density accounted for 
edge effects of microfluidic device branching. After 24 h, samples were serum 
starved. All time point designations (e.g. Day 1, Day 2, etc.) are relative to time in 
serum-free growth medium. 
 
3.3.1.4 Staining and Imaging of Tissue Structure 
Samples were fixed in 4% paraformaldehyde after 1, 2, 4, 7, 10, or 14 days 
and stored in PBS at 4 °C for concurrent staining. Tissues were treated with Triton 
X-100 for permeabilization, then stained with mouse anti-paxillin primary antibody 
(BD Transduction Laboratories) labeled with Alexa Fluor 546 (Life Technologies) 
secondary antibodies. Nuclei and f-actin fibers were stained with DAPI (Life 
Technologies) and Alexa Fluor 488 phalloidin (Life Technologies), respectively. 
Mounted samples were imaged with an Olympus IX81ZDC microscope with Disk 
Spinning Unit confocal attachment (Olympus).   
 
3.3.1.5 Analysis of Tissue Structure 
Tissue confluence and alignment were analyzed via staining of f-actin 
filaments (phalloidin) and nuclei (DAPI). Percent confluence was determined by 
thresholding actin images and calculating the percent coverage in each of ten 
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random fields of view within a single tissue. Tissue alignment was analyzed using 
both f-actin and nuclei images. Orientation order parameters (OOPs) for actin 
images were calculated as previously published [84, 146, 160]. Orientations were 
recorded for ten random fields of view on each single tissue with an OOP 
calculated for the total tissue. Nuclear orientation was quantified by fitting an ellipse 
to each individual nucleus in DAPI images and calculating a vector along the major 
axis of the resulting ellipse [161]. The orientations of these vectors were analyzed 
similar to actin orientation to find a nuclear OOP for each single tissue. Nuclear 
eccentricity, ε, for each nucleus was calculated from the fitted ellipses using, 
𝜀 = √1 − (
𝑚𝑖𝑛𝑜𝑟 𝑎𝑥𝑖𝑠 𝑙𝑒𝑛𝑔𝑡ℎ
𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠 𝑙𝑒𝑛𝑔𝑡ℎ
)
2
.  (Eq. 3.1) 
Tissue thickness was measured as in Alford et al. [84] using f-actin confocal 
images. 
 
3.3.1.6 Focal Adhesion Analysis 
Paxillin was imaged at 60x magnification to assess focal adhesion (FA) 
density and plaque area as in Xing et al. [162]. Briefly, autothresholding of images 
was completed using a rolling ball background subtraction plugin for ImageJ. A 
single round of dilation and erosion was then applied to ensure complete FA 
fidelity. A particle analysis function in ImageJ was then used to quantify FA 
properties. FAs were defined as continuous particles containing no fewer than 10 
pixels (~0.11 µm2 [163]) and no greater than 2000 pixels (~23 µm2 [164]). FA area 
was calculated as the average plaque area in pixels converted to microns using 
known microscope objective parameters. FA density was determined using an 
ImageJ particle analysis algorithm to quantify plaque counts and normalizing 
counts to the calculated field of view area. FA area and density values from ten 
random locations were averaged for each tissue.   
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3.3.2 Vascular Muscular Thin Films 
Vascular muscular thin film (vMTF) constructs were fabricated according to 
previous methods [160]. Briefly, a 5-mm strip of poly(N-isopropylacrylamide) 
(PIPAAm, Polysciences, Inc.) dissolved in 1-butanol was spin coated across the 
center of the cover slip (Fig. 3.1 B). PDMS doped with 1.0 µm fluorescent 
microspheres (Polysciences, Inc.) at a concentration of <0.01% by volume was 
spin coated on top of the PIPAAm and then cured at 65 °C for 4 h. 
 
3.3.2.1 MTF Contractility Assay 
Tissue function was assessed using a MTF contractility assay. At the time 
of the experiment, a series of cuts were made as in Grosberg et al. [160], yielding 
eight parallel MTFs. Samples were cooled below 32 °C to dissolve the PIPAAm 
strip and release the MTFs (Fig. 3.1 C). The sample was then transferred to a dish 
containing Tyrode’s solution (1.192 g HEPES, 0.901 g glucose, 0.265 g CaCl2, 
0.203 g MgCl2, 0.403 g KCl, 7.889 g NaCl, and 0.040 g NaH2PO4 per liter of 
ddH2O) maintained at 37 °C using a LCS-1 Thermal Cooling Module and Quick 
Exchange Heated/Cooled Platform (Warner Instruments). MTFs damaged during 
cutting were removed prior to the start of the contractility assay.  
A Lumar V12 stereomicroscope (Carl Zeiss) was used to capture 
transmitted and fluorescent light images of MTFs every 30 s for 60 min. Tissues 
were allowed to equilibrate. They were then serially stimulated, first with 50 nM 
endothelin-1 to induce contraction [84], then with 100 µM HA-1077 (Sigma-
Aldrich), a rho kinase inhibitor, to induce relaxation.  
 
3.3.2.2 Analysis of Tissue Stress 
Tissue stress in MTFs during the contractility assay was analyzed using 
custom MATLAB code built upon previously reported methods [15, 160]. Projection 
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lengths were used to determine radius of curvature in each MTF as in Grosberg et 
al. [160]. The mean cross-sectional stress was calculated from the observed radius 
of curvature and measured thickness and stiffness of the tissue and PDMS layers 
as previously published [15] (Fig. 3.1 C). Every fourth substrate sample was 
retained for PDMS thickness evaluation via a Tencor P-10 stylus profilometer 
(KLA-Tencor). Relationships between spin coating time and thickness were 
determined for every set of MTF cover slips. 
Two stress states were used for comparison of VSMC contractile function. 
Basal tone was calculated by subtracting initial stress in the tissue at equilibrium 
from the stress in the tissue after HA-1077 inhibition of contraction. Induced 
contraction was calculated as the increase in stress due to application of 
endothelin-1. Mean values of both stress states were calculated for both µCP and 
Gen+FN fabrication techniques at Days 1, 2, 4, and 7. Tissues on Gen+FN were 
also tested on Days 10 and 14. µCP tissues were only maintained through Day 7 
due to loss of tissue integrity.  
 
3.3.2.3 Assessment of Tissue Metabolic Activity 
Gen+FN tissue metabolic activity was assessed using an XTT (2,3-bis[2-
Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) 
toxicology assay (Sigma-Aldrich) [165]. Briefly, Gen+FN tissues at Days 1, 2, 4, 7, 
10 and 14 were treated with 500 µL of 0.2 mg/ml XTT in Tyrode’s solution and 
incubated for 4 h at 37°C. Solutions were resuspended and two 250 µL samples 
were transferred to a 96-well plate for absorbance readings. Absorbance at 450 
nm and 690 nm was recorded using a plate reader (Bio-Tek). Absorbance values 
with background and blank values subtracted were normalized to Day 1 values.  
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3.3.2.4 Assessment of Cell Viability 
Gen+FN cell viability was measured using a calcein AM live/dead assay 
(Life Technologies) [166]. Gen+FN tissues were incubated in 2 µM calcein AM and 
4 µM ethidium homodimer-1 (Life Technologies) for 45 min, followed by a 10 min 
Hoechst staining for nuclei. Live samples were imaged at 20x with an Olympus 
IX81ZDC microscope with Disk Spinning Unit confocal attachment. Nuclei were 
counted by fitting an ellipse to each individual nucleus in Hoechst images. Dead 
cells were manually counted in ethidium homodimer-1 images and subtracted from 
nuclei counts to yield number of live cells. Live cell values were normalized to Day 
1 values. A linear best fit of the ratio of normalized XTT metabolic activity to 
normalized live cell counts at each time point was also calculated.  
 
3.3.3 Statistical Analysis 
Statistical comparisons for actin confluence and actin and nuclear 
alignment involved a natural logarithmic transformation of mean values for each 
condition (day and fabrication method) to account for unequal variance, followed 
by ANOVA with a Tukey pairwise multiple comparisons test. Contractility results 
were compared using ANOVA to determine if any significant differences occurred 
between fabrication techniques.        
 
3.4 Results 
3.4.1 Tissue Fabrication and Confluence Analysis 
We aimed to develop a tissue microfabrication method that yields the high 
fidelity tissue structure of µCP, but with extended tissue viability necessary to study 
chronic vascular disease. To do this, we developed a microfluidic ECM deposition 
device for patterning genipin on PDMS substrates (see 3.3.1.2 for details). To 
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compare this method to more traditional methods, we considered three tissue 
construction methods: µCP, microfluidic delivery of FN only, and serial microfluidic 
delivery of genipin and FN (Gen+FN). In each case, the result of the 
micropatterning was 10-µm-wide lines of FN with a 10-µm pitch between (Fig. 3.1 
A).  
For each patterning protocol, when cells were seeded, they self-organized 
into aligned monolayers (Fig. 3.2). The tissues were then serum starved to induce 
an in vivo-like contractile phenotype [167] and incubated for 1-14 days in serum-
free medium. Daily transmitted light images were captured to assess tissue 
integrity over time. Qualitatively, no differences were seen until Day 7, with 
noticeable decreases in tissue confluence and integrity starting at Day 7 in FN only 
and Day 10 in µCP (Fig. 3.2). Only sparse individual cells remained at Day 14 for 
both FN only and µCP samples. Gen+FN yielded confluent tissues throughout the 
course of two weeks that appear to maintain their integrity longer than tissues 
grown on PDMS without genipin modification. Tissue samples were fixed on Days 
1, 2, 4, 7, 10, and 14 and stained for f-actin to quantitatively assess confluence. 
Cytoskeletal coverage was assessed via immunostaining for f-actin filaments. 
Images showed highly-confluent, anisotropic structure of f-actin filaments for both 
µCP and microfluidic delivery fabrication methods (Fig. 3.3 A). Using image 
thresholding (see 3.3.1.6 for details), we found that percent confluence of actin 
filaments showed consistent confluence through two weeks in tissues fabricated 
on Gen+FN substrates. Tissues fabricated on unmodified substrates displayed 
statistically significant decreases between Day 10 and Day 14, suggesting loss of 
tissue integrity and viability (Fig. 3.3 B). 
 
3.4.2 Vascular Tissue Structure 
Smooth muscle cells in arteries are aligned approximately circumferentially 
about the vessel in concentric lamellar sheets [5]. Thus, our in vitro model must 
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reproduce this highly-aligned tissue structure in addition to maintaining confluence. 
To assess tissue alignment, we characterized subcellular organization of tissues 
constructed with each of our three fabrication methods over a two-week incubation 
period. Alignment of f-actin filaments was quantitatively assessed using an 
orientational order parameter (OOP), where an OOP of 1.0 represents a perfectly 
aligned tissue and an OOP of 0.0 represents a perfectly isotropic tissue. OOP was 
>0.8 for all fabrication methods for Days 1-7 (Fig. 3.3 C). The µCP and FN only 
OOP decreased steadily after Day 7, consistent with the decrease in confluence 
(Fig. 3.3 B), further suggesting a loss of tissue integrity in conditions without 
genipin modification of PDMS. However, alignment was maintained through Day 
14 for Gen+FN substrates, with OOP >0.74 throughout the time course.  
To provide a more comprehensive analysis of subcellular tissue structure, 
we also considered nuclear alignment and shape. We expected nuclear alignment 
to mirror actin alignment based on prior work [84]. To determine if this persisted 
on Gen+FN substrates, OOP was also determined for nuclei across all three 
conditions. As expected, nuclear OOP results mirrored those of actin OOP (Fig. 
3.3 D). In addition to nuclear alignment, nuclear eccentricity was also analyzed. 
We have previously found that nuclear eccentricity increased with increased 
VSMC contractility [84]. Here, no discernable trend existed in nuclear eccentricity 
across the fabrication techniques over time (Fig. 3.3 E), though nuclear eccentricity 
generally decreased over the culture time for each technique.  
Focal adhesion (FA) maturation, which can be characterized by FA area 
and density, has been correlated with force generation in the cytoskeleton and are 
indicative of a contractile phenotype in VSMCs [168]. To determine whether VSMC 
maturation occurred with increasing culture time on Gen+FN samples, we 
immunostained for paxillin, an integral FA protein. Images of paxillin were used to 
quantitatively measure focal adhesions over time (Fig. 3.4 A, see Methods for 
details). A binary mask was used to quantify FA area and density (Fig. 3.4 B). 
Paxillin plaque area was found to be consistent over time, with a slight increase on 
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Day 7 (Fig. 3.4 C). FA density was also found to be consistent across all time 
points, with a slight decrease on Day 7 (Fig. 3.4 D). These results suggest 
maintenance of consistent tissue structure and maturity on Gen+FN substrates for 
the full two-week incubation.   
 
3.4.3 MTF Analysis of Tissue Function 
The importance of pathologic changes in VSMC function in vascular 
disease drove our interest in developing a method for assessing contractility over 
time scales longer than currently possible. We hypothesized that stress would 
remain consistent over time for viable tissues. To test this hypothesis, we 
employed vascular MTFs to directly measure VSMC function. Comparisons 
between traditional µCP and novel microfluidic patterning techniques were made 
to determine the viability of Gen+FN substrates for long-term vascular contractility 
assays with MTFs. MTFs consisted of a monolayer of VSMCs patterned on a thin 
layer of PDMS. As the tissue contracts, the passive PDMS layer bends (Fig. 3.5 
A). The radius of curvature of the MTF is used to measure stress over time (Fig. 
3.5 B). Tissues were serially stimulated with endothelin-1 (ET-1) to induce 
contraction and the rho-associated protein kinase inhibitor HA-1077 to induce 
relaxation. Gen+FN samples were evaluated on Days 1, 2, 4, 7, 10, and 14. Due 
to decreased tissue integrity at Day 10 on µCP substrates (Fig. 3.2), µCP tissue 
contractility was only assessed through Day 7. 
Two tissue contractility measures were used to compare tissue fabrication 
techniques’ effects on function: basal tone, which describes the contraction of the 
tissue with no external stimulation, and induced contractility, which is the additional 
stress due to ET-1 stimulation. Basal tone in µCP tissues started low at Day 1 
(3.2±1.1 kPa) and steadily increased through Day 7, where the maximum basal 
tone was 4.1±0.8 kPa (Fig. 3.5 C). Gen+FN tissues demonstrated consistent basal 
tone throughout two weeks, with an average basal tone of 2.5±0.2 kPa over the 
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whole period (Fig. 3.5 C). Calculation of induced contraction yielded a nearly 
identical trend across the fabrication methods through Day 7. Both start high (~1 
kPa) and decrease over time (Fig. 3.5 D). Tissue metabolic activity measured as 
change in absorbance due to reduction of the tetrazolium ring in XTT to formazan 
decreased over time, as did the number of live cells (Fig. 3.5 E). The ratio of these 
values remained relatively constant throughout the time course (Fig. 3.5 E, red 
dotted line). However, Gen+FN tissues showed the ability to contract on Day 14, 
suggesting a viable, fully-functional arterial tissue mimic for long-term 
experimentation.   
 
3.5 Discussion 
VSMC function is important for maintaining homeostasis in arteries. 
Maladaptive perturbation of VSMCs has also been implicated in a wide variety of 
vascular diseases, including hypertension [70], vasospasm [132], and aneurysm 
[135]. The central role of VSMC function in arterial growth and remodeling has led 
to development of mathematical [73, 169-174]and experimental [61, 78, 120, 145, 
175] models of vascular disease states. Previous methods for isolating VSMC-
driven disease mechanisms fail either to provide a simple readout of function or to 
recapitulate VSMC function over relevant time scales. Thus, long-term models 
must be developed to comprehensively investigate the mechanisms of vascular 
disease. 
Here, we adapted our MTF assay for long-term studies by patterning the 
passive PDMS layer with genipin. Genipin adsorption yields a modified PDMS 
substrate, presenting hydrophilic residues for protein deposition and maintenance 
of focal adhesions. As cells remodel the ECM, the crosslinking property of genipin 
supports sustained adhesion of VSCMs to PDMS substrates. In substrates without 
genipin surface modification, ECM remodeling causes steady deterioration of 
adhesion and results in observed release and death of VSMCs. We found that 
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MTFs constructed on genipin-modified substrates remained viable for up to one 
week longer than those patterned using µCP or FN adsorption. This result 
suggests that genipin modification of PDMS is a viable method for long-term 
culture of VSMCs that can be implemented in the study and modeling of various 
vascular disease mechanisms and the associated mechanics of vascular tissues.    
We found generally good correlation between Gen+FN MTFs and µCP 
MTFs in the early stages of tissue development. The one outlier we found was Day 
7 basal tone (Fig. 3.5 C). We believe, however, that the elevated tone in the µCP 
tissues is an artifact of our method, which cannot account for tissue disconnecting 
from the substrate. Our stress measurement method assumes that the tissue layer 
of the MTF is fully connected to the PDMS layer. However, we have observed that 
in MTFs where cellular connection to the PDMS substrate is compromised, the 
tissue often locally separates, forming tissue bridges that can cause increased 
MTF curvature, and thus, increased perceived stress. Though we did not directly 
observe any bridges in the results presented here, we believe the elevated stress 
measured is due to microbridge formation and not to increased contractility in 
these samples. 
Our results suggest decreased performance of MTFs at late stages of the 
assay, primarily between Day 10 and Day 14. We found both decreased induced 
contractility (Fig. 3.5 D) and decreased metabolic activity (Fig. 3.5 E) over time. 
This brings into question the viability of the presented assay at later time points. 
However, we also show a decrease in viable cells at later time points. This is 
expected as a result of culturing tissues in serum-free medium for extended time 
courses, mimicking the in situ conditions surrounding VSMCs in healthy arteries. 
VSMCs cultured in serum-free medium have been reported to have improved 
contractile properties and shift toward a contractile phenotype [167]. Contractile 
VSMCs rarely proliferate. Thus, over time, dead cells are not replaced in tissues 
cultured in serum-free conditions. The decreases in induced contractility and 
metabolic activity can be correlated to decreases in viable VSMCs in our tissues, 
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suggesting VSMC performance and function are not affected by genipin surface 
modification. To avoid this viable VSMC loss, futher studies may be performed with 
a small basal level of serum to allow greater cell proliferation and, thus, live VSMC 
population maintanence.  
Long-term models of VSMC function are important because VSMCs play a 
critical role in both adaptive and maladaptive arterial growth and remodeling that 
can occur over on the scale of weeks, months, or even years. Pathogenesis of 
cerebral vasospasm has been shown to occur over 3-7 days post-injury with 
characteristic hypercontractility followed by responsive arterial remodeling [18, 
132]. Hypertension studies have suggested that smooth muscle growth and 
collagen remodeling are critical factors in long-term structural changes to arteries 
[176, 177]. Rapid changes in artery residual stress (2-10 days) in hypertension 
models suggest non-uniform remodeling within arterial walls due to non-uniform 
stress distribution caused by increased pressure [6, 71]. Fridez et al. found that 
the early stages of hypertensive remodeling are primarily due to VSMC adaptation 
and hypercontractility with ECM remodeling playing a role later in the process, 
returning arterial basal tone to normal levels [178]. Jackson et al. showed VSMC 
proliferation and ECM remodeling occur in the vessel wall when longitudinal 
tension is applied, returning the artery to a normal strain state over time [121]. 
Computational models also suggest that there is a direct correlation between 
mechanical forces applied to VSMCs and these long-term remodeling phenomena 
[73, 171, 179-181]. However, the mechanotransduction pathways involved are not 
well established. Our extended MTF assay could provide a robust assay for 
studying these early stages of mechano-adaptation in chronic vascular diseases 
with the experimental control to isolate cell-signaling pathways. Extending the 
previous MTF method from 2-3 days to up to 14 days allows for broadened 
applicability and provides a more comprehensive method for studying disease 
pathways involving maladaptive remodeling.  
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While our current studies focus on cellular function, our results suggest 
MTFs could also be used to study the evolving interaction of cells with their ECM 
environment. We found that FA structural variation in Gen+FN samples (Fig. 3.4 
C,D) corresponded temporally with both loss of tissue integrity (Fig. 3.2) and 
elevated apparent contractility in µCP samples (Fig. 3.5 C). We found a decrease 
in alignment of both actin (Fig. 3.3 C) and nuclei (Fig. 3.3 D) from Day 7 to 10 in 
all samples. In the µCP and FN only samples, this loss of alignment precedes 
delamination, but in Gen+FN samples, the alignment recovers by Day 14. At these 
time points, FA size decreased (Fig. 3.4 C) and density increased (Fig. 3.4 D), 
consistent with nascent FA formation [168, 182, 183]. This result suggests that the 
initially patterned FN is being replaced by cell-generated ECM in the Gen+FN 
samples. This aspect of our long-term MTF assay could be employed to study the 
dynamics of cell stress generation during ECM remodeling processes.   
 
3.6 Conclusions 
Here, we report a method for studying smooth muscle contractility in vitro 
over physiologically-relevant time scales by modifying our previous MTF assay. 
We functionalized PDMS substrates with genipin to sustain long-term culture of 
VSMCs. We validated our method by comparing the structure and function of 
tissues fabricated on substrates with genipin modification with traditional MTF 
construction methods. Genipin-modified MTFs yielded tissues with high alignment, 
sufficiently mimicking the circumferential alignment of VSMCs in arteries. In 
addition, these tissues showed sustained tissue contractility and integrity 
throughout two weeks, greatly improving upon previous fabrication techniques. 
Our assay allows for studies of pathological function and arterial growth and 
remodeling and can be integrated into an artery-on-a-chip system (see Appendix 
A) for pharmacological screening of treatment strategies for vascular disease. 
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Figure 3.1. Extracellular matrix patterning and muscular thin film methods. 
(A) Microcontact printing (μCP) and microfluidic (μFluidic) delivery procedures. 
Left: Scanning electron microscopy images of PDMS stamps (µCP) and µFluidic 
devices (scale bar: 50 µm). Center: µCP and µFluidic device methods for ECM 
deposition. Right: Immunostained FN (scale bar: 50 µm). Far right: Cell seeding of 
FN-patterned substrates. (B) Tissue construct structure for MTF experiments. 
(Green: PIPAAm, brown: PDMS, Blue: glass cover slip, Red: cells, Purple: focal 
adhesions, Yellow: fibronectin, Black: genipin). Left bottom inset: Non-genipin-
modified substrates. Right bottom inset: Genipin-modified substrates. (C) 
Schematic representation of MTF release. Inset: Representative transmural stress 
in the PDMS and cell layers. 
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Figure 3.2. Tissues constructed on genipin-modified substrates maintain 
viability longer than traditional methods. 
Representative transmitted light images of tissues constructed using three 
fabrication techniques: 1) traditional μCP of fibronectin (μCP) 2) fibronectin 
delivered via microfluidic device (FN only) 3) genipin and fibronectin delivered via 
microfluidic device (Gen+FN). Time represents days after serum-starvation of 
tissues. (Scale bars: 200 μm). 
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Figure 3.3. Tissues constructed on genipin-modified substrates maintain 
confluence and subcellular organization longer than those constructed 
using traditional methods. 
(A) Immunofluorescent images of tissues (green: f-actin, blue: nuclei, μCP: 
microcontact printing of fibronectin, FN only: microfluidic delivery of fibronectin 
only, Gen+FN: microfluidic delivery of genipin followed by fibronectin, Scale bar: 
100 μm). (B) Percent tissue confluence as measured by actin coverage. (*: 
significantly different from FN only and µCP, p<0.05, error bars: standard error, 
µCP: n=3-6, FN only: n=4-8, Gen+FN: n=3-7). (C) Orientation order parameter 
(OOP) of f-actin filaments (†: significantly different from FN only, p<0.05, Error 
bars: standard error, µCP: n=3-6, FN only: n=4-8, Gen+FN: n=3-7). (D) OOP for 
nuclei (†: significantly different from FN only, p<0.05, Error bars: standard error, 
µCP: n=3-6, FN only: n=4-8, Gen+FN: n=2-7). (E) Nuclear eccentricities (box: 
25%-75%, bars: 10%-90%, Black thin line: median, Red thick line: mean, µCP: 
n=3-6, FN only: n=4-8, Gen+FN: n=2-7). 
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Figure 3.4. Focal adhesion size and density are consistent with time in 
Gen+FN tissues. 
(A) Representative immunofluorescent images of tissues immunostained for the 
focal adhesion protein paxillin (red, Scale bar: 50 μm). (B) Representative binary 
masks of confocal images for determining FA area and density (White: FA, Scale 
bar: 50 µm) (C) FA area. (D) FA density. All graphs: mean ± standard error, n=3-
4. 
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Figure 3.5. VSMC contractility is maintained throughout the course of two 
weeks and comparable to our traditional MTF technique. 
(A) Top: Representative transmitted light images of MTFs at critical points of 
contractility assay (scale bar: 1 mm). Bottom: Side view schematics of relative MTF 
curvature. (B) Characteristic stress curve for quantitative analysis of contractility. 
Induced contraction by ET-1 and basal tone are normalized to the initial equilibrium 
stress in the tissue. (C) Basal tone (error bars: standard error, µCP, squares: n=8-
18, G+FN, circles: n=5-12). (D) Induced contractility (error bars: standard error, 
µCP, squares: n=8-18, G+FN, circles: n=5-12). (E) XTT metabolic activity 
(squares, short dashed line) and live VSMC cell count (circles, long dashed line) 
normalized to Day 1 values. Red linear best fit (dotted line) of the ratio of 
normalized XTT activity to live VSMC cell count over 14 days (error bars: 
normalized standard error, XTT metabolic activity: n=4-9, Live VSMC count: n=2-
4). 
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Chapter 4. Subarachnoid Hemorrhage-Associated Factors 
Influence on Vascular Smooth Muscle Contractility  
 
This chapter contains material adapted from an invited original research article at 
JBME and is reproduced with permission. Hald ES, Timm CD, and Alford PW. In 
Press. Amyloid Beta Influences Vascular Smooth Muscle Contractility and 
Mechano-Adaptation. It is also based on previously submitted research abstracts 
for the 2015 and 2016 Summer Biomechanics, Bioengineering, and Biotransport 
Conferences.  
 
4.1 Summary 
Subarachnoid hemorrhage can lead to abnormal and elevated exposure of 
the cerebral vasculature to a variety of blood and clotting factors. It is also a 
common precursor to the development of cerebral vasospasm, a mechanically-
defined vascular disease that can lead to severe ischemia and even death of 
patients. The direct effects of the factors released during hemorrhage on vascular 
functional contractility are largely unknown. Here, we measured the individual 
effects of treatment with three common factors released and/or elevated during 
hemorrhage: transforming growth factor-beta (TGF-β1), platelet-derived growth 
factor (PDGF), and thrombin. We found that TGF-β1 and PDGF treatment yields 
minimal effect on VSMC functional contractility. Thrombin treatment results in 
decreased VSMC basal tone after 24h. We also assessed the functional 
phenotypic consequences of all three factors, finding factor-dependent shifts in 
VSMC synthetic and contractile phenotypes. These findings suggest further study 
is needed to fully elucidate the importance of specific SAH-related factors in the 
progression of cerebral vasospasm. 
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4.2 Introduction 
Subarachnoid hemorrhage (SAH) is bleeding in the subarachnoid space of 
the brain, often a result of traumatic brain injury or intracranial aneurysm [132]. 
When SAH occurs, growth and clotting factors, such as TGF-β, PDGF, and 
thrombin, are released (see Fig. 2.1) [18]. Surrounding tissues exposed to elevated 
levels of these factors in the blood, cerebrospinal fluid, and brain interstitial fluid 
[184-186] can undergo a variety of mechanical and biochemical perturbations 
affecting both vascular and neural function. Cerebral vasospasm (CVS) is a 
potentially lethal vascular disease that often occurs after SAH and is characterized 
by acute hypercontractile arterial behavior followed by extended remodeling, 
lumen occlusion, and ischemia over the course of 3-7 days after a bleed occurs 
[132]. It is unclear what initiates this characteristic functional behavior in CVS 
progression, resulting in limited therapeutic options to reduce negative patient 
outcomes associated with CVS. 
Vascular smooth muscle cells (VSMCs) typically exist in a distribution 
between two functional phenotypes: contractile or synthetic (proliferative) [74]. 
During CVS, the distribution of VSMC phenotypes is thought to relate to tissue-
level mechanics in the cerebral vasculature [187]. A growth and remodeling 
response to the acute hypercontractility is an observed hallmark of the disease. 
This growth and remodeling typically begins a few days after hemorrhage, resulting 
in a significant shift of VSMC population toward a proliferative synthetic phenotype 
[61]. Hypertrophy and proliferation of VSMCs results in thickening of cerebral 
arterial walls, which, in turn, can further exacerbate the effects of CVS, leading to 
severe ischemia due to luminal narrowing [30]. Factors released after hemorrhage 
have been implicated in VSMC phenotypic switching (see Fig. 2.2) and could 
contribute to progression of CVS. However, these effects have not been studied 
at the single VSMC scale. 
Here, we utilize a traction force microscopy method to determine changes 
in VSMC mechanics resulting from differential treatment with SAH factors. We find 
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minimal differences in single VSMC mechanical output when treated with TGF-β1 
and PDGF. Decreased VSMC function occurs acutely with thrombin treatment, but 
also leads to VSMC death or detachment over time. We also consider a distribution 
of VSMCs between synthetic and contractile functional phenotypes, how treatment 
with individual SAH-borne factors affects shifts in these distributions, and to what 
extent these factors may be critical in the pathologic mechanical progression of 
CVS. 
 
4.3 Methods 
4.3.1 Polyacrylamide Gel Fabrication and VSMC Culture 
Polyacrylamide (PA) gels were fabricated as described by Tse and Engler 
[188] and tuned to a Young’s modulus of 13.5 kPa. Gels were doped with 2% v/v 
200-nm diameter red fluorescent microspheres to allow substrate displacement 
tracking. A 6.5-µL drop of PA gel solution was placed on 3% bind silane-
functionalized cover slips. A clean 12-mm glass cover slip was placed on top of 
the gel drop to yield a uniform PA gel of thickness ~50 µm upon gel curing (Fig. 
4.1). Cured PA gels were coated with 0.2 mg/ml sulfosuccinimidyl-6-(4’-azido-2’-
nitrophenylamino)-hexanoate (Sulfo-SANPAH, Thermo Scientific, Rockford, IL) to 
covalently bond 50 ug/ml human fibronectin (Corning, Bedford, MA) to PA gel 
surfaces (Fig. 4.1) [189]. PDMS rings (18-mm diameter) were attached to reduce 
cell seeding area and required medium volume.  
Human umbilical cord artery VSMCs (Lonza, Walkersvile, MD) were 
cultured in growth medium composed of M199 medium with 10% FBS, 10 mM 
HEPES, 1X Non-Essential Amino Acids, 3.5 g/L glucose, 2mM L-glutamine, 1% 
penicillin/streptomycin, and 2 mg/L Vitamin B12 supplement. For all cell structure 
and function assays, passages 5-7 were used to sparsely seed polyacrylamide 
constructs (~5000 cells per construct) (Fig. 4.1).  
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4.3.2 SAH-factor Treatment Assays 
After attachment, each sample containing sparsely-seeded VSMCs on PA 
gels were serum-starved for 24h to induce a contractile functional phenotype 
characteristic of normal arterial wall conditions [167]. Stock solutions of 
transforming growth factor-1 (TGF-β1, 10 ug/mL in 4 mM HCl with 1% bovine 
serum albumin, R&D Systems), platelet-derived growth factor (PDGF, 10 ug/mL in 
4 mM HCl, R&D Systems), and thrombin (100 units/mL in 0.1% bovine serum 
albumin, Sigma-Aldrich) were prepared. Experimental solutions were made by 
dilution of stock solutions in serum-free growth medium. After 24h in serum-free 
medium, VSMCs were then treated with prescribed treatment solutions at one of 
five physiologic or pathologic concentrations (including control). For multi-day 
assays, treatment solutions were refreshed every 24h. 
 
4.3.3 VSMC Functional Measurement 
Mechanical function of VSMCs was measured by calculating the total strain 
energy of the substrate due to cell traction. This total strain energy, 𝑈, was 
calculated for two stress states: (1) basal tone via tissue relaxation with HA-1077, 
a rho-kinase inhibitor, and (2) ET-1-induced contraction (Fig. 4.2 A). Basal tone 
strain energy was calculated using the bead displacement field resulting from the 
difference between images captured at equilibrium and 30 min post HA-1077 
treatment (Fig. 4.2 B, right). Similarly, ET-1-induced contraction strain energy was 
calculated using the bead displacement field resulting from the difference between 
images captured 10 min post ET-1 treatment and at equilibrium (Fig. 4.2 B, left). 
Experiments were conducted for sparsely-seeded single VSMCs attached to 13.5 
kPa PA gels. Control and treatment samples were run concurrently. Cells were 
maintained in a physiologic Tyrode’s solution (7.889 g NaCl, 1.192 g HEPES, 
0.901 g glucose, 0.403 g KCl, 0.265 g CaCl2, 0.203 g MgCl2, and 0.040 g NaH2PO4 
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per liter of ddH2O). Physiological temperature was maintained within a heating 
chamber attached to an Olympus IX81ZDC microscope. Brightfield images of 
single VSMCs and z-stacks of their underlying bead-doped substrates were 
captured at four time points: equilibrium, 10 min post 50nM endothelin-1 treatment, 
30 minutes post 100mM HA-1077 treatment, and post cell lysis with 5% sodium 
dodecyl sulfate. 
Traction force microscopy techniques were used to determine a single 
quantitative measurement of single VSMC mechanical output [190]. Template 
matching between fluorescent bead images from two different time points was 
completed using an ImageJ template matching algorithm [190]. Particle image 
velocimetry using iterative interrogation windows of 128-64-32 pixel width was 
completed between the matched bead images from the same cell location at 
different time points [190]. Noise filtering of the resulting displacement field was 
conducted by manually sampling an area outside of the cell tractions (field area) 
and subtracting the mean displacement (“field displacement”) from all 
displacements. Displacements with value less than the mean of the modified 
displacements within the field area plus five standard deviations were considered 
noise and removed prior to further analysis. The noise-filtered displacement field 
was used to calculate traction stresses with a Fourier transform traction cytometry 
(FTTC) ImageJ plugin [190]. A Poisson’s ratio of 0.48, a Young’s modulus of 13.5 
kPa, and a regularization factor of 1e-9 were used for all FTTC calculations. Total 
strain energy of the substrate, 𝑈, was calculated for each individual VSMC using  
𝑈 =
1
2
∫𝑻∙ 𝒖 𝑑𝑥𝑑𝑦  (Eq. 4.1) 
where 𝑻 is the traction stress and 𝒖 is the displacement. 
Total strain energies were normalized to Day 1 control. Outlier analysis was 
conducted to remove all values above or below means by more than 1.5 times the 
interquartile range. Statistical comparisons for all experimental results were 
determined using Kruskal-Willis One Way ANOVA on Ranks and a Dunn’s Method 
for pairwise multiple comparisons and a significance level of p<0.05. 
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4.3.4 VSMC Functional Phenotype Population Assessment 
 VSMC functional phenotype was quantitatively assessed using total strain 
energy for each cell normalized by Day 1 control means for each set of 
experiments. A threshold of 1.0 (i.e. Day 1 control mean) was used to determine 
percentage of cells above functional phenotype threshold (contractile) and below 
functional phenotype threshold (synthetic) for all experimental groups. Differences 
between treatment conditions and same day controls were calculated as percent 
difference in fraction of contractile cells.  
 
4.4 Results 
4.4.1 TGF-β1 and PDGF Do Not Influence VSMC Functional Contractility 
We sought to determine the functional effects of exposure to a variety of 
single SAH-borne factors on VSMCs. We applied natural human TGF-β1 and 
PDGF to VSMCs seeded on polyacrylamide (PA) gels (Fig. 4.1). We used traction 
force microscopy to quantify total strain energy in the gels due to VSMC traction 
forces (Fig. 4.2). Chronic treatment with TGF-β1 largely yielded no changes in 
VSMC functional contractility, with the exception of an acute decrease in induced 
contraction observed for 100 pM treatment on Day 1 (Fig. 4.3). Similarly, PDGF 
chronic treatment also yielded minimal effects on VSMC contractility (Fig. 4.4). 
Taken together, these data suggest that TGF-β1 and PDGF do not significantly 
affect VSMC function. 
 
4.4.2 Thrombin Reduces VSMC Functional Contractility and Viability 
Thrombin is a considered to be a significant vasoconstrictor in the complex 
milieu of blood-borne biochemical factors [48]. Acute increases in contraction 
caused by thrombin exposure could result in a cascade leading to downstream 
proliferation in the growth and remodeling response to heightened vessel wall 
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stress. We sought to recapitulate this temporal cascade in single VSMCs treated 
with thrombin. Interestingly, we found significant decreases in acute basal function 
(Fig. 4.5). This effect was maintained through 48h of treatment for the highest 
concentration of thrombin treatment. Further, we observed drastic detachment and 
apoptosis of VSMCs treated with any concentration of thrombin for four days. 
These results suggest our assay is ill-equipped to capture thrombin effects on 
VSMC function.  
 
4.4.3 Evaluation of Functional Phenotypic Populations 
Given the apparent inability of our traction force microscopy assay to 
capture changes in VSMC function as a function of total strain energy, we took a 
closer look at the distribution of single VSMC total strain energy values. In many 
cases, cell populations appeared to be bimodal in nature. This led us to consider 
VSMC functional phenotype as an alternative metric for analysis. In doing so, we 
found that TGF-β1 treatment initially resulted in fewer contractile cells, as 
measured in basal tone and induced contraction stress states and represented as 
negative percent differences (Fig. 4.6, Row 1). The percentage of contractile cells 
increased for both states by Day 4 (Fig. 4.6, Row 1). PDGF treatment resulted in 
increased contractile functional phenotype for basal tone, but decreased 
contractile phenotype for induced contraction across all time points (Fig. 4.6, Row 
2). Thrombin yielded dose-dependent responses in functional phenotypes related 
to induced contraction (Fig 4.6, Row 3). These results suggest a more 
comprehensive study of VSMC phenotypic changes in response to factor 
treatment may provide key information implicating or exonerating factor roles in 
CVS progression. 
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4.5 Discussion 
Basal tone and induced contraction are important stress states due to the 
mechanical responses they elicit. It has been hypothesized that tissues have a 
preferred local stress and that they grow to maintain this stress [68]. Changes in 
this target stress, as measured by changes in basal tone here, result in growth rate 
changes. The initial decrease in functional basal tone induced by TGF-β (and 
thrombin), followed by increased functional basal tone over time (Fig. 4.6) may 
mirror the acute hypercontractile behavior in CVS and the increased growth and 
remodeling experienced in prolonged CVS, despite being counterintuitive (i.e. 
fewer contractile cells should result in decreased contraction). Similarly, by this 
consideration, PDGF appears to promote growth and remodeling at all times, 
possibly being critical in later stages of CVS.   
In developing the traction force microscopy assay presented here, we 
consulted previously reported literature values to determine proper SAH-factor 
levels for treatment. A closer comparison of these values to those logarithmic 
concentrations used experimentally may explain the apparent limits of our assay 
in discerning changes in VSMC functional mechanics. Douglas et al. found an 
increase in TGF-β1 concentration from normal levels of 4 pM to 57 pM 1-5 days 
post hemorrhage [184]. If the effects of TGF-β1 are finely-tuned as a function of 
concentration, our treatment concentrations may not capture the in vivo behavior. 
Further, Kitazawa and Tada reported that changes in TGF-β concentration at later 
time points in CVS progression are minimal, yet heightened relative to normal 
levels [191]. This suggests that TGF-β may play a more critical role in chronic CVS 
progression compared to acute, which is supported by our counterintuitive 
interpretation of the functional phenotypic effects observed in response to TGF-β 
treatment (Fig. 4.6). Thrombin is reported to drastically decrease in concentration 
from 120 ng/ml at 2h post hemorrhage to 4.7 ng/ml at 48h post hemorrhage [192]. 
This timeframe suggests thrombin could be an ideal candidate for driving CVS 
mechanical progression, specifically due to its function as a vasoconstrictor. Our 
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experimental time points could miss the hyper-acute effects of thrombin and should 
be investigated in the future.   
Endothelin-1-induced contraction is representative of VSMCs’ ability to 
actively contract in maintenance of endothelial shear stress. In CVS, shear stress 
increases due to luminal narrowing [30]. This should result in decreased endothelin 
response, suggesting the shift toward synthetic phenotype observed in PDGF 
induced contraction (Fig. 4.6) could be important in CVS progression. Further work 
to rigorously predict the effects of pathologic changes in functional phenotype 
distributions on tissue response and the downstream consequences for arterial 
blood flow in the brain can be accomplished via computational modeling. These 
results represent behavior of sparse single VSMCs exposed to three factors known 
to increase in abundance as a result of SAH. VSMCs in native arteries experience 
much different architecture and surroundings, including cell-cell contacts and 
signaling. We can extend this work to investigate differences between “injured” 
solitary VSMCs and intact vascular architecture using a vascular muscular thin film 
technique as detailed in Chapter 3 and Appendix A, yielding a more complete 
understanding of the influence of SAH factors on cerebral vascular mechanics.  
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Figure 4.1. Polyacrylamide gel fabrication and sparse VSMC seeding. 
Top left: A drop of polyacrylamide (PA, blue) is sandwiched between a bind-silane-
functionalized cover slip (bottom, gray) and a 12-mm diameter glass cover slip 
(top, gray), forming a uniform gel of ~50 µm thickness. Top right: Fibronectin 
(green) is uniformly bonded to the PA gel surface via sulfo-SANPAH covalent 
bonding. Bottom left: VSMCs (red) are sparsely seeded on fibronectin-coated 
surface at a seeding density of ~5000 cells per sample. Inset: 10x phase contrast 
image of sparsely-seeded VSMCs attached to substrate.  
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Figure 4.2. Traction force microscopy to determine functional mechanical 
output of single VSMCs. 
(A) 40x brightfield images of a single VSMC cultured on polyacrylamide gel at three 
critical time points during a functional contractility assay: 1) Equilibrium; 2) Induced 
contraction via endothelin-1 treatment; 3) Relaxation via rho kinase inhibition with 
HA-1077. (B) Heat maps of corresponding displacement fields [190] in the 
polyacrylamide gels due to cell tractions for two important stress states: 1) Induced 
Contraction (IC, ET-1 – Equilibrium); 2) Basal Tone (BT, Equilibrium – HA-1077). 
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Figure 4.3. Effects of chronic transforming growth factor beta 1 (TGF-β1) 
treatment on VSMC functional contractility. 
Chronic TGF-β1 treatment with four different treatment concentrations (pico-molar) 
for 1, 2, and 4 days has limited effect on basal tone and induced contraction of 
VSMCs as a function of total strain energy in PA gel substrates due to cell tractions 
(normalized to Day 1 controls). Box: 25-75%, Whiskers: 10-90%, Red Line: Mean, 
Black Line: Median, *: p<0.05. 
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Figure 4.4. Effects of chronic platelet-derived growth factor (PDGF) treatment 
on VSMC functional contractility. 
Chronic PDGF treatment with four different treatment concentrations (pg/mL or 
ng/mL) for 1, 2, and 4 days has limited effect on basal tone and induced contraction 
of VSMCs as a function of total strain energy in PA gel substrates due to cell 
tractions (normalized to Day 1 controls). Box: 25-75%, Whiskers: 10-90%, Red 
Line: Mean, Black Line: Median, *: p<0.05. 
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Figure 4.5. Effects of chronic thrombin treatment on VSMC functional 
contractility. 
Chronic thrombin treatment with four different treatment concentrations (ng/mL) for 
one and two days (high rate of cell detachment/apoptosis by Day 4) significantly 
decreases basal tone on Day 1. On Day 2, basal function is significantly decreased 
for high concentration of thrombin (1000 ng/mL), and ET-1-induced contraction 
shows steady increase with increasing concentration. Total strain energy in the PA 
gel due to cell tractions are all normalized to Day 1 controls. Box: 25-75%, 
Whiskers: 10-90%, Red Line: Mean, Black Line: Median, *: p<0.05. 
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Figure 4.6. SAH factor-induced temporal functional phenotype distribution 
differences. 
Treatment of VSMCs with three individual SAH factors (TGF-β1, PDGF, and 
Thrombin) induces different distributions of contractile and synthetic functional 
phenotypes. % Diff is relative to same day control contractile population (>1.0 
threshold normalized to Day 1 control mean). Negative % Diff: more synthetic, % 
Diff: more contractile, 1: TGF-β1, Row 2: PDGF, Row 3: Thrombin. 
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Chapter 5. Amyloid Beta Influences Vascular Smooth Muscle 
Contractility and Mechano-Adaptation 
 
This chapter contains material for an invited original research article at JBME and 
is reproduced with permission. Hald ES, Timm CD, and Alford PW. In Press. 
Amyloid Beta Influences Vascular Smooth Muscle Contractility and Mechano-
Adaptation. 
 
5.1 Summary 
Amyloid beta accumulation in neuronal and cerebrovascular tissue is a key 
precursor to development of Alzheimer’s disease and can result in 
neurodegeneration. While its persistence in Alzheimer’s cases is well-studied, 
amyloid beta’s direct effect on vascular function is unclear. Here, we measured the 
effect of amyloid beta treatment on vascular smooth muscle cell functional 
contractility and modeled the mechano-adaptive growth and remodeling response 
to these functional perturbations. We found that the amyloid beta 1-42 isoform 
induced a reduction in vascular smooth muscle cell mechanical output and 
reduced response to vasocontractile cues. These data were used to develop a 
thin-walled constrained mixture arterial model that suggests vessel growth and 
remodeling in response to amyloid beta-mediated alteration of smooth muscle 
function leads to decreased ability of cerebrovascular vessels to vasodilate. These 
findings provide a possible explanation for the vascular injury and malfunction 
often associated with the development of neurodegeneration in Alzheimer’s 
disease. 
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5.2 Introduction 
Alzheimer’s disease is a neurodegenerative disease diagnosed by 
dementia and the presence of amyloid beta (A𝛽) plaques in the brain, most often 
in the elderly [193]. Aβ is a peptide formed by proteolytic cleavage of the amyloid 
precursor protein that can exist in both soluble monomeric and insoluble dimeric 
forms [194]. Typically, soluble Aβ is cleared from the neurovascular space via 
transport across the blood brain barrier (BBB) facilitated by low-density lipoprotein 
receptor-related protein 1 (LRP1) [195]. Disruptions in this clearance may lead to 
the formation of the insoluble plaques pervasive in Alzheimer’s disease. These 
plaques, along with neurofibrillary tangles, are posited to result in direct insult to 
neurons in the cerebral cortex, providing the framework for the amyloid hypothesis 
in Alzheimer’s disease development.  
Aβ deposition is also a hallmark of cerebral amyloid angiopathy (CAA), 
which is present in over 80% of Alzheimer’s patients and is a common precursor 
to Alzheimer’s disease [16]. Aβ plaques can form in and around the 
cerebrovasculature with pathological effects on the function of cerebral arteries, 
disruption of the BBB, and changes in cerebral blood flow [2]. Two abundant 
isoforms of the Aβ peptide, 1-40 and 1-42, have been implicated in the 
development of CAA. Aβ 1-42 is the initial [196, 197] and more persistent [198] 
component of Aβ plaques that form in the media of arteries or wrap around the 
exterior arterial wall in CAA. The exact mechanisms by which Aβ induces arterial 
dysfunction in CAA are unclear, but it has been shown that cerebrovascular 
dysfunction can directly result in neuronal loss, a possible link to Alzheimer’s 
disease progression [2]. Using transgenic Alzheimer’s disease mouse models, 
Han et al. [17] found that CAA impacts vascular smooth muscle cell (VSMC)-
mediated vasodilatory response. CAA also results in altered arterial wall structure 
[17, 199], and increased collagen deposition has been observed in cerebral 
arteries of Alzheimer’s patients [200]. However, it is unclear how arterial structural 
adaptation in Alzheimer’s disease affects vascular function.  
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Experimental evidence suggests three possible causes of vascular 
dysfunction in CAA: 1) physical inhibition of vasodilation by Aβ plaques, 2) 
limitation of VSMC dynamics due to physical alteration of the arterial wall, 3) 
alteration of VSMC contractile dynamics. Here, we focus on the role of VSMC 
contractile dynamics and consider the effects of changes in vessel wall 
composition on vasodilatory behavior during arterial growth and remodeling. Using 
traction force microscopy, we find that direct exposure to Aβ 1-42 induces 
significant decreases in basal stress and active contraction of VSMCs. To relate 
this finding to the adaptive response of cerebral arteries, we develop a constrained 
mixture model relating the change in VSMC basal stress to alteration of vessel 
function. We find that decreased VSMC function combined with a compensatory 
increase in collagen production can explain the decreased dynamic range and lost 
vasodilatory function of cerebral arteries in CAA patients. This work suggests the 
effects of Aβ on VSMC function and arterial structure may lead to the pathological 
cerebrovascular behavior that contributes to the progression of Alzheimer’s 
disease as a result of CAA. 
5.3 Methods: Experiment 
5.3.1 Polyacrylamide Gel Fabrication and VSMC Culture 
Polyacrylamide (PA) gels were fabricated as described by Tse and Engler 
[188]. Uniaxial stretch experiments were used to calculate a Young’s modulus of 
13.5±2.2 kPa for PA gels composed of: 10/0.13% w/v acrylamide/bis-acrylamide 
with 0.002/0.05% w/v initiators tetramethylethylenediamine/ammonium persulfate 
in 1X phosphate buffered saline solution. For traction force microscopy assays, 
gels were doped with 2% v/v 0.2-µm diameter red fluorescent microspheres. A 6.5-
µL drop of PA gel solution was placed on 3% bind silane-functionalized cover slips. 
A clean 12-mm glass cover slip was placed on top of the gel drop to yield a uniform 
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PA gel of thickness ~50 µm upon gel curing. Cured PA gels were coated with 0.2 
mg/ml sulfosuccinimidyl-6-(4’-azido-2’-nitrophenylamino)-hexanoate (Sulfo-
SANPAH, Thermo Scientific, Rockford, IL) to covalently bond 50 ug/ml human 
fibronectin (Corning, Bedford, MA) to PA gel surfaces. 
Human umbilical cord artery VSMCs (Lonza, Walkersvile, MD) were 
cultured in growth medium composed of M199 medium with 10% FBS, 10 mM 
HEPES, 1X Non-Essential Amino Acids, 3.5 g/L glucose, 2mM L-glutamine, 1% 
penicillin/streptomycin, and 2 mg/L Vitamin B12 supplement.  For all cell structure 
and function assays, passages 5-7 were used to sparsely seed polyacrylamide 
constructs (~5000 cells per construct).  
 
5.3.2 Amyloid Beta Treatment Assays 
Sparsely-seeded VSMCs on PA gels were serum-starved after attachment 
for 24h to induce a physiologic contractile phenotype [167]. Stock solutions of 
amyloid beta peptides 1-40 (1 mg/ml in ddH2O, APExBIO, Houston, TX) and 1-42 
(1 mg/ml in 50 mM Tris buffer, Tocris Bioscience, Bristol, UK) were prepared. 
Experimental solutions were made by dilution of stock solutions in serum-free 
growth medium. Cells were then treated with prescribed treatment concentrations. 
For Day 2 and Day 4 assays, treatment solutions were changed every 24h. 
 
5.3.2.1 VSMC Structure and Amyloid Beta Plaque Analysis 
Treated VSMCs on PA gels were fixed in 4% paraformaldehyde and stained 
using immunofluorescence techniques. Briefly, cells were permeabilized with 
0.05% Triton X-100, then blocked with 10% bovine serum albumin. Amyloid beta 
was stained using 1:200 rabbit polyclonal anti-amyloid fibril primary antibody (EMD 
Millipore, Temecula, CA) labeled with 1:200 Alexa Fluor 546 (Life Technologies, 
Eugene, OR) secondary antibody. F-actin and nuclei were stained with 1:200 
Alexa Fluor 488 phalloidin (Life Technologies) and DAPI (Life Technologies), 
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respectively. Fluorescent images were acquired at 40x magnification with an 
Olympus IX81ZDC microscope.  
Immuno-labeled amyloid beta fibrils were quantitatively analyzed using 
techniques similar to focal adhesion analysis of Xing et al. [162]. Single VSMCs 
were manually traced using ImageJ to determine cell areas. Pixel values outside 
the cell area were set to zero. An ImageJ rolling ball background subtraction plugin 
was used to autothreshold images. Images were then made binary, followed by 
sequential dilation and erosion steps. The ImageJ particle analysis function was 
used to quantify pixels with signal representing presence of amyloid beta 
fibrils/plaques. Total amyloid beta coverage was normalized by cell area for each 
individual cell, yielding percent coverage of amyloid beta. 
Nuclei morphology was analyzed by thresholding DAPI images and fitting 
an ellipse to each single nucleus [161]. Nuclear eccentricity, 𝜀, was calculated from 
the major and minor axis measurements according to  
𝜀 = √1 − (
𝑚𝑖𝑛𝑜𝑟 𝑎𝑥𝑖𝑠 𝑙𝑒𝑛𝑔𝑡ℎ
𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠 𝑙𝑒𝑛𝑔𝑡ℎ
)
2
. (Eq. 5.1) 
 
5.3.2.2 VSMC Functional Measurement 
Mechanical function of VSMCs was measured by calculating the total strain 
energy of the substrate due to cell traction. To do so, traction force microscopy 
techniques were used [190]. Template matching between fluorescent bead images 
from two different time points was completed using Matlab’s image registration 
function. Particle image velocimetry using iterative interrogation windows of 128-
64-32 pixel width was completed between the matched bead images from the 
same cell location at different time points [190]. Noise filtering of the resulting 
displacement field was conducted by manually sampling an area outside of the cell 
tractions (field area) and removing all displacements less than the mean 
displacement of the field area plus five standard deviations. The noise-filtered 
displacement field  was used to calculate traction stresses with a Fourier transform 
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traction cytometry (FTTC) ImageJ plugin [190]. A Poisson’s ratio of 0.48, a Young’s 
modulus of 13.5 kPa, and a regularization factor of 1e-9 were used for all FTTC 
calculations. Total strain energy of the substrate, 𝑈, was calculated for each 
individual VSMC using  
𝑈 =
1
2
∫𝑻∙ 𝒖 𝑑𝑥𝑑𝑦  (Eq. 5.2) 
where 𝑻 is the traction stress and 𝒖 is the displacement. 
Traction force microscopy experiments were conducted for sparsely-
seeded single VSMCs attached to 13.5 kPa PA gels. Control and treatment 
samples were run concurrently. Cells were maintained in a physiologic Tyrode’s 
solution (7.889 g NaCl, 1.192 g HEPES, 0.901 g glucose, 0.403 g KCl, 0.265 g 
CaCl2, 0.203 g MgCl2, and 0.040 g NaH2PO4 per liter of ddH2O). Physiological 
temperature was maintained within a heating chamber attached to an Olympus 
IX81ZDC microscope. Brightfield images of single VSMCs and z-stacks of their 
underlying bead-doped substrates were captured at four time points: equilibrium, 
10 min post 50nM endothelin-1 treatment, 30 minutes post 100mM HA-1077 
treatment, and post cell lysis with 5% sodium dodecyl sulfate. 
Total strain energy, 𝑈, was calculated for two stress states: (1) basal tone 
and (2) ET-1-induced contraction. Basal tone strain energy was calculated using 
the bead displacement field resulting from the difference between images captured 
at equilibrium and 30 min post HA-1077 treatment. Similarly, ET-1-induced 
contraction strain energy was calculated using the bead displacement field 
resulting from the difference between images captured 10 min post ET-1 treatment 
and at equilibrium. Total strain energies were normalized to Day 1 control.  Outlier 
analysis was conducted to remove all values above or below means by more than 
1.5 times the interquartile range. Statistical comparisons for all experimental 
results were determined using Kruskal-Willis One Way ANOVA on Ranks and a 
Dunn’s Method for pairwise multiple comparisons and a significance level of 
p<0.05.   
 
 61 
 
5.4 Methods: Model 
The model is a thin-walled, pseudo-elastic, incompressible pressurized 
cylinder composed of a constrained mixture of VSMCs, collagen, and elastin. The 
ECM components are treated as one-dimensional fibers within a VSMC scaffold. 
VSMCs are treated as transversely isotropic and contractile. ECM turnover is 
treated as previously described [180], wherein old fibers decay and are replaced 
by new fibers at a specified initial stretch ratio. Smooth muscle grows both radially 
and circumferentially. All growth and remodeling acts to maintain the muscle at a 
specified “target” stress and maintain luminal blood shear stress.  
The model was used to test how a change in the VSMC target stress or 
contractile tone caused by Aβ accumulation might affect the global mechanics and 
function of the vessel. Two growth and remodeling modes were considered: 
1) Total growth: Adaptation occurs through increased vessel volume, with 
volume fractions of each constituent conserved. 
2) Collagen deposition: Adaptation occurs through altered collagen content 
with the volume of the other constituents remaining constant, altering the 
volume fractions of collagen, smooth muscle, and elastin. 
In all models, the temporal dynamics of growth and remodeling were not 
considered; only the final homeostatic equilibrium state was examined. 
 
5.4.1 Analysis 
The model combines volumetric growth theory [8], pseudo-contraction 
[170], and collagen remodeling [201] to study how alteration of smooth muscle 
stress and contractility affects vessel mechanics. The fundamental assumption is 
that all of the components in the vessel wall move and deform together, but that 
each constituent has an evolving natural, zero-stress configuration. 
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5.4.2 Growth and Remodeling Theory  
The loaded homeostatic state at time 𝑡 = 0 is taken as the reference 
configuration denoted as 𝑏(0) (Fig. 5.1). The constituents are constrained to move 
together, so that each constituent undergoes deformation, denoted by deformation 
gradient tensor 𝑭, resulting in the current configuration 𝑏(𝑡). However, the 
constituents are treated separately because the zero-stress configuration of each 
can evolve independent of the other constituents. The deformation from the zero-
stress configuration of constituent 𝑖 (𝐵𝑖) to 𝑏(𝑡) is given by its elastic deformation 
gradient tensor 𝑭∗𝒊. The method by which a constituent’s zero-stress configuration 
evolves varies by constituent. 
In the case of smooth muscle cells, suppose each cell is separated from 
every other cell and the ECM, giving configuration 𝐵𝑚. Because the cells are 
unconstrained, they are stress-free. In this unconstrained configuration, the cells 
can grow via either hypertrophy or hyperplasia. The deformation due to growth is 
described by the growth tensor 𝑮. Following growth, the cells’ new stress-free 
configuration is given by 𝐵𝑔
𝑚. VSMCs can also contract, further altering their zero-
stress configuration to 𝐵𝑎
𝑚 via the activation tensor 𝑨. When the cells are 
reassembled and the vessel is loaded, the elastic deformation from 𝐵𝑎
𝑚 to 𝑏(𝑡) is 
given by 𝑭∗𝒎 (Fig. 5.1). 
Collagen is treated as fibers that are produced and degraded with time. 
Between 𝑡 = 0 and some time 𝑡 = 𝜏, the vessel can undergo a deformation 𝑭𝟎 𝝉⁄ . 
When a collagen fiber is produced at time 𝜏, its stress-free configuration is given 
by 𝐵𝑐. The fiber is then inserted into the matrix by the cell at an initial stretch ratio, 
𝜆𝑜
𝑐 . Further deformation from time 𝜏 to the current time 𝑡 is given by deformation 
gradient tensor 𝑭𝝉 𝒕⁄ , and the elastic deformation from the zero-stress configuration 
𝐵𝑐 to the current configuration 𝑏(𝑡) is given by 𝑭∗𝒄 (Fig. 5.1). Elastin is assumed to 
undergo a similar remodeling protocol, though it is known that elastin remodeling 
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is temporally limited [202, 203]. The elastic deformation from the elastin zero-
stress configuration 𝐵𝑒 to the current configuration 𝑏(𝑡) is given by 𝑭∗𝒆 (Fig. 5.1). 
 
5.4.3 Deformation and Mechanical Equilibrium 
The deformation of the loaded artery 𝑏(𝑡) relative to reference state 𝑏(0) is 
described by the mapping 
𝑟 = 𝑟(𝑅),   𝜃 = Θ,    𝑧 = Λ𝑍 (Eq. 5.3) 
for uniform inflation of a cylinder, where (𝑅, Θ, 𝑍) and (𝑟, 𝜃, 𝑧) are the cylindrical 
polar coordinates of a point in 𝑏(0) and 𝑏(𝑡), respectively. The deformation 
gradient tensor 𝑭 = 𝑑𝑖𝑎𝑔[𝜆𝑟 , 𝜆𝜃, 𝜆𝑧] is given by 
𝜆𝑟 =
𝑅
𝑟Λ
=
ℎ
𝐻
  ,        𝜆𝜃 =
𝑟
𝑅
  ,        𝜆𝑧 = Λ (Eq. 5.4) 
where ℎ and  𝐻 are the wall thicknesses in 𝑏(0) and 𝑏(𝑡), respectively, and Λ is 
the axial stretch ratio. 
The equation for radial equilibrium is given by 
𝜕𝜎𝑟
𝜕𝑟
+
𝜎𝑟+𝜎𝜃
𝑟
= 0 (Eq. 5.5) 
where 𝜎𝑖 are the Cauchy stresses. For a thin-walled cylinder with an internal 
pressure of 𝑃 and wall thickness ℎ, this simplifies to an equation for circumferential 
wall stress given by 
𝜎𝜃 =
𝑃𝑟
ℎ
. (Eq. 5.6) 
The fluid shear stress (𝜏𝑤) on the endothelium is approximated by 
Poiseuille flow, given by 
𝜏𝑤 =
4𝜇𝑄
𝜋𝑟3
 (Eq. 5.7) 
where 𝑄 is the volumetric blood flow rate, and 𝜇 is the viscosity of the blood (3 cp). 
We used pial artery pressure and flow rates given by 𝑃 = 30 𝑚𝑚𝐻𝑔 (4 𝑘𝑃𝑎) and 
𝑄 = 0.242 µ𝐿/𝑠 [204].  
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5.4.4 Material Constitutive Laws 
We let 𝑭∗𝒋 = 𝑑𝑖𝑎𝑔[𝜆𝑟
∗𝑗 , 𝜆𝜃
∗𝑗, 𝜆𝑧
∗𝑗] be the deformation gradient tensor of 
constituent 𝑗 relative to its zero-stress configuration. For an incompressible 
pseudo-elastic material, the Cauchy stress is given by 
𝜎𝑖
𝑗 = 𝜆𝑖
∗𝑗 𝜕𝑊𝑗
𝜕𝜆
𝑖
∗𝑗 − 𝑝 (Eq. 5.8) 
where 𝑗 represents the constituent (elastin, collagen, smooth muscle), 𝑖 is the 
coordinate axis (𝑟, 𝜃, or 𝑧), 𝑊𝑗 is the constituent strain-energy density function, 
and 𝑝 is a Lagrange multiplier. 
We let 𝑉𝑗 be the volume of the tissue composed of constituent 𝑗. The volume 
fraction of constituent 𝑗 is given by  
𝜙𝑗 =
𝑉𝑗
∑ 𝑉𝑗𝑗
 (Eq. 5.9)  
and ∑ 𝜙𝑗 = 1𝑗 . The total Cauchy stress of the mixture is given by 
𝜎𝑖 = ∑ 𝜙
𝑗𝜎𝑖
𝑗
𝑗 . (Eq. 5.10) 
 
5.4.4.1 Elastin 
The strain-energy density for elastin is taken as 
𝑊𝑒 =
𝐶𝑒
2
(𝜆𝜃
∗𝑒2 + 𝜆𝑧
∗𝑒2 + 𝜆𝜃
∗𝑒−2𝜆𝑧
∗𝑒−2 − 3) (Eq. 5.11) 
where 𝐶𝑒 is a material parameter taken to be 24.91 kPa based on Cheng et al. 
[174].  Elastin does not significantly remodel post-birth [203]. We assumed that the 
elastin in the model was at a mature homeostatic stretch 𝜆𝑜
𝑒  in the loaded 
configuration so that 𝜆𝜃
∗𝑒 = 𝜆𝑧
∗𝑒 = 𝜆𝑜
𝑒 . In all models, we let 𝜆𝑜
𝑒 = 1.1. 
 
5.4.4.2 Collagen  
The strain-energy density for collagen is taken as 
𝑊𝑐 = ∑
𝐶𝑐
𝛽
(𝑒𝛽(𝐼4
∗𝑘−1)
2
− 1)2𝑘=1  (Eq. 5.12) 
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where 𝐶𝑐 and 𝛽 are material parameters taken to be 42.32 kPa and 0.08, 
respectively, based on Cheng et al. [174]. 𝐼4 is the 4
th strain invariant given by 𝐼4
∗ =
𝐶𝜃𝜃
∗ cos2(𝛼𝑘) + 2𝐶𝜃𝑧
∗ sin(𝛼𝑘) cos(𝛼𝑘) + 𝐶𝑧𝑧
∗ sin2(𝛼𝑘), where 𝐶𝑖𝑗
∗  is the 𝑖, 𝑗 component 
of the elastic right Cauchy-Green tensor, defined as 𝑪∗ = 𝑭∗𝑻 ∙ 𝑭∗, and 𝛼 is the 
angle of the collagen fibers with respect to the undeformed circumferential 
orientation. Humphrey and Rajagopal proposed that when collagen turns over, old 
fibers are replaced by new fibers at a preferred stretch ratio 𝜆𝑜
𝑐  [201]. Here, we 
assume that the vessel is at homeostasis and has been for some time, so that 
𝜆𝑖
∗𝑐 = 𝜆𝑜
𝑐  for all fibers in the loaded configuration, and we assume 𝜆𝑜
𝑐 = 1.2. 
 
5.4.4.3 Vascular Smooth Muscle  
Smooth muscle strain energy is taken as 
𝑊𝑚 =
𝐶𝑚
2
(𝐼1
∗ − 3) +
𝐴𝑚
2
(𝜆𝜃
∗𝑚 − 1)2 (Eq. 5.13) 
where 𝐶𝑚 and 𝐴𝑚 are material parameters taken to be 10 kPa and 100 kPa, 
respectively. 𝐼1
∗ is the first strain invariant with respect to the zero-stress 
configuration, given by 𝐼1
∗ = 𝜆𝑟
∗𝑚 2 + 𝜆𝜃
∗𝑚 2 + 𝜆𝑧
∗𝑚 2. Muscle acts to adapt the vessel 
quickly to changes in its mechanics via contraction, but to do so, it must maintain 
a homeostatic partially-contracted state described by the stress-free cell 
shortening 𝜆𝑎𝑜 [9]. In all models, we assumed that the loaded active artery is at 
this homeostasis, and VSMC contractile cytoskeletons are primarily oriented 
circumferentially, so that 𝑨 = 𝑑𝑖𝑎𝑔[1, 𝜆𝑎𝑜 , 1]. VSMCs can also grow via hypertrophy 
or proliferation to alter their stress. Though axial growth and remodeling plays an 
important role in vessel mechanics [73, 205, 206], here, we ignored its effect and 
only included radial growth (thickening) 𝜆𝑔𝑟 and circumferential growth 𝜆𝑔𝜃. Thus, 
the growth tensor is given by 𝑮 = 𝑑𝑖𝑎𝑔[𝜆𝑔𝑟 , 𝜆𝑔𝜃, 1]. 
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5.4.5 Mechano-adaptation Models 
Three mechano-adaptation models were considered: total growth, collagen 
deposition, and altered contraction/collagen deposition. 
 
5.4.5.1 Total Growth 
The central assumption of the total growth model is that all constituents 
increase or decrease in volume equally to maintain homeostasis. The arterial wall 
acutely contracts and chronically grows via cytoskeletal remodeling to maintain 
endothelial shear stress [9]. Here, we ignore acute contraction and assume that, 
at homeostasis, actin stress-free shortening is equal to 𝜆𝑎𝑜, which we set to 0.8. 
Thus, long-term maintenance of shear is achieved through the growth tensor 𝑮. 
We assume that circumferential growth is governed by fluid shear stress via the 
relation 
?̇?𝑔𝜃
𝜆𝑔𝜃
= 𝐴(𝜏𝑤 − 𝜏𝑜) (Eq. 5.14) 
where ?̇?𝑔𝜃 is the derivative with respect to time of 𝜆𝑔𝜃, 𝐴 is a constant, 𝜏𝑤 is the 
luminal blood shear stress (Eq. 5.7), and 𝜏𝑜 is the optimal shear stress, assumed 
to be 15 dyne/cm2 [207]. In addition, the wall grows thicker or thinner to maintain 
VSMC target stress. Radial growth is given by 
?̇?𝑔𝑟
𝜆𝑔𝑟
= 𝐵(𝜎𝜃
𝑚 − 𝜎𝑜) (Eq. 5.15) 
where 𝐵 is a constant, and 𝜎𝑜 is the target stress, assumed to be 75 kPa. In the 
total growth model, the relative volume of constituents remains constant, i.e. 𝜙𝑖 is 
constant for all 𝑖, so the change in volume due to VSMC growth is equally reflected 
in the collagen and elastin. Similar to Intengan et al. [208], we use 𝜙𝑐 = 0.23, 𝜙𝑒 =
0.17, 𝜙𝑚 = 0.60 in this model for small arteries. 
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5.4.5.2 Collagen Deposition 
In the collagen deposition model, we assumed that increased thickening of 
the vessel is due to additional deposition of collagen, not VSMC growth or elastin 
deposition. This model uses the growth formulation of the total growth model, but 
adds the relation  
?̇?𝑐 =
?̇?𝑔𝑟
𝜆𝑔𝑟
∑ 𝑉𝑗𝑗  (Eq. 5.16) 
where 𝑉𝑐 is the volume of collagen, and 𝑗 is collagen, elastin, and smooth muscle. 
The VSMC and elastin volumes remain constant, resulting in altered volume 
fractions of each constituent (Eq. 5.9). 
 
5.4.5.3 Altered Contraction/Collagen Deposition 
The altered contraction model uses the growth and collagen deposition 
formulation of the collagen deposition model.  In addition, the homeostatic stress-
free shortening (𝜆𝑎𝑜) is prescribed over the range 0.55-0.95 to test how contractile 
tone affects remodeling. 
 
5.4.6 Numerical Implementation 
The governing equations were solved using a Nelder-Mead minimization. 
Initially, 𝜆𝑔𝑟 and 𝜆𝑔𝜃 were iterated, while all other parameters were held constant 
until 𝜎𝜃
𝑚 = 𝜎𝑜 and 𝜏𝑤 = 𝜏𝑜. Target stress, 𝜎𝑜 ,  was then incremented and, 
depending on the mechano-adaptation method, 𝜆𝑔𝑟, 𝜆𝑔𝜃, and/or 𝜙
𝑐 were solved 
using finite differences until 𝜎𝜃
𝑚 = 𝜎𝑜 and 𝜏𝑤 = 𝜏𝑜 with error criterion of 1 ×
10−12 𝑃𝑎. Pressure-radius curves were calculated by holding all parameters 
constant except 𝑃 (𝜆𝑎 = 𝜆𝑎𝑜 for active curves, 𝜆𝑎 = 1 for passive curves) and 
calculating the resulting radius. Vasodilation data were calculated as the ratio of 
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the vessel radius of the passive vessel at physiologic pressure to the radius of the 
active vessel at physiologic pressure. 
 
5.4.7 Parameter Determination 
When possible, parameters were determined from the literature. The 
parameters 𝜎𝑜, 𝜆𝑜
𝑒 , 𝜆𝑜
𝑐 , 𝐶𝑚 , 𝐴𝑚, and 𝜆𝑎𝑜 were set to yield a pressure-radius behavior 
that matches those experimentally measured by Steelmann et al. [204]. We 
conducted parameter studies to determine the influence of certain parameters on 
the vessel growth and remodeling mechanical response in the collagen deposition 
case (see Appendix B). Here, we only studied the homeostatic implications of 
remodeling, not the temporal course, so we used unitless time in Eqs. 5.14-5.16. 
For all models, the growth parameters 𝐴 and 𝐵 were 3 × 10−4 𝑃𝑎−1𝑡𝑖𝑚𝑒𝑠𝑡𝑒𝑝−1 and 
1 × 10−7 𝑃𝑎−1𝑡𝑖𝑚𝑒𝑠𝑡𝑒𝑝−1, respectively. 
5.5 Results 
5.5.1 Amyloid Beta Does Not Influence Intracellular Morphology 
We sought to determine the effects of exposure to Aβ on VSMCs. We 
applied natural human Aβ 1-42 to VSMCs seeded on polyacrylamide (PA) gels 
and found plaque aggregation of Aβ within 24 hours after initial treatment. 
Aggregation increased with increasing treatment concentration (Fig. 5.2 A). This 
was consistent with previous studies showing synthetic human Aβ 1-42 fibril 
plaque formation occurs in vitro [209]. Quantitative assessment of Aβ plaque 
coverage showed increasing plaque coverage with increasing A𝛽 concentration. 
In the highest concentration group (10 𝜇M A𝛽), 40% of the cell area was plaque 
covered (Fig. 5.2 B,C).  
Cell spread area is known to affect cell traction stress [210], so we 
measured the effect of Aβ treatment on VSMC spread area and found that it was 
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consistent across all treatment groups (Fig. 5.2 D). Nuclear morphology has been 
previously shown to correlate to changes in VSMC function [84, 211], so we 
measured the eccentricity of the nuclei in Aβ-treated VSMCs. We found a non-
significant increasing trend in nuclear eccentricity as Aβ treatment concentration 
increased (Fig. 5.2 E). Taken together, these data demonstrate that Aβ treatment 
does not significantly affect VSMC architecture. 
5.5.2 Amyloid Beta Influences VSMC Functional Contractility 
Changes in VSMC functional contractility could mediate cerebrovascular 
dysfunction associated with Alzheimer’s disease [2]. We sought to determine the 
influence of Aβ accumulation on VSMC function. We used traction force 
microscopy to calculate total strain energy in polyacrylamide (PA) gels due to 
VSMC traction forces (Fig. 5.3 A,B).  Generally, exposure to Aβ caused a decrease 
in the basal strain energy. Treatment with 100 nM and 10 µM Aβ 1-42 yielded 
significant decreases in normalized total strain energy relative to control after 24h, 
though surprisingly, 1 µM Aβ 1-42 did not (Fig. 5.3 C). We found similar trends in 
decreased VSMC basal contractility after 48h and 96h of treatment (Fig. 5.3 D,E). 
Treatment with Aβ 1-40 did not show any effect on basal strain energy (data not 
shown).  
Cerebral blood flow is tightly regulated by neural activation [3], requiring a 
highly-dynamic cerebral vasculature. To determine the effect of Aβ on VSMC 
active contraction, we measured the strain energy generated by VSMCs exposed 
to the vasoconstrictor endothelin-1 (ET-1). Similar to our basal tone data (Fig. 5.3 
C), we found decreased ET-1-induced contractility after 24h of treatment with Aβ 
1-42 (Fig. 5.3 F), suggesting that decreasing tone corresponds with a more general 
loss of contractile dynamics. See Appendix C for additional functional contractility 
investigation.  
 
5.5.3 Growth and Remodeling Affects Vessel Properties and Vasodilation 
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We sought to investigate the impact Aβ-mediated loss of VSMC functional 
contractility has on arterial function at the tissue scale. To do so, we developed a 
thin-walled, constrained mixture model (see Fig. 5.1) for the cerebral vasculature 
in which the artery can undergo remodeling through growth and remodeling. We 
assumed that the VSMCs have a preferred target stress, which correlates with the 
basal strain energy measured in PA gels due to individual cell traction (Fig. 5.3 C). 
We asked how alteration of the target stress due to Aβ exposure might affect 
vessel growth and remodeling. We considered two growth and remodeling cases: 
total growth and collagen deposition.  
In the total growth case, as the target stress was decreased, the vessel wall 
thickened and the volume fractions of cells and collagen remained constant (Fig. 
5.4 A). In addition, the circumferential growth (𝜆𝑔𝜃) needed to maintain endothelial 
shear increased as target stress decreased (Fig. 5.4 B). Pressure-radius curves 
for varying target stresses shifted, showing increasing apparent stiffness in the 
modeled vessel with decreasing target stress (Fig. 5.4 C). Han et al. found that 
cerebral arteries in a transgenic mouse model expressing mutant amyloid 
precursor protein displayed a decreased ability to vasodilate [17]. We tested the 
effect of total growth on vasodilation by simulating the change in radius when 
VSMC tone is relaxed. As the ratio of the radius of the passive artery to the radius 
of the actively-contracted artery approaches one, vasodilation becomes fully-
attenuated. We found that the ability of the vessel to relax decreases with 
decreasing target stress (Fig. 5.4 D). 
In the collagen deposition case, the vessel wall thickened, the amount of 
collagen increased, and the volume fraction of smooth muscle cells decreased with 
decreasing target stress (Fig. 5.5 A). Similar to total growth, circumferential growth 
(𝜆𝑔𝜃) increased as target stress decreased (Fig. 5.5 B), and pressure-radius curves 
showed increasing apparent stiffness with decreasing target stress (Fig. 5.5 C). 
This stiffening was more severe than was observed in the total growth model.  
When we tested the ability of the vessel to vasodilate, we again saw decreased 
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dilation with decreasing target stress (Fig. 5.5 D). This decrease was markedly 
sharper than the one seen in the total growth model. 
Next, we asked how the observed loss of the ability of VSMCs to actively 
contract (see Fig. 5.3 F) could affect vessel growth and remodeling. This 
decreased contractility can be represented as an increase in the homeostatic 
active stretch ratio (𝜆𝑎𝑜) in our model. We considered the effect of altered 
contractility within the collagen deposition model. We found that as 𝜆𝑎𝑜 increases, 
the pressure-radius curve of the activated vessel becomes less stiff and the 
passive vessel becomes stiffer (Fig. 5.6 A). In addition, the ability of the vessel to 
dilate severely decreases for all target stresses as active contractility is decreased 
(Fig. 5.6 B). Combined decrease in target stress and ability of VSMCs to actively 
contract resulted in greater attenuation of vasodilation.  These data suggest that 
growth and remodeling due to changes in both VSMC target stress and ability of 
VSMCs to contract resulting from exposure to Aβ could contribute to the observed 
attenuation of vasodilatory response in CAA and Alzheimer’s disease. 
 
5.6 Discussion 
Arterial dysfunction can play an important role in Alzheimer’s disease 
development. To date, the effect of Aβ exposure on VSMC force generation and 
functional contractility, and the downstream implications these effects have on 
arterial growth and remodeling, are not known.  
Here, we directly measured the contractility of VSMCs to determine the 
influence of Aβ exposure on their function. We found significant decreases in basal 
tone and induced contraction when treated with Aβ 1-42 (Fig. 5.3 C-F).  Previous 
work has shown induction of apoptosis in VSMCs cultured in vitro or on Aβ-coated 
substrates [212, 213]. We did not observe this in our assays utilizing media-
contained Aβ treatment of VSMCs attached to PA gels and do not believe 
apoptosis contributed to our findings. Interestingly, Aβ concentrations that yielded 
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both minimal and significant plaque formation (Fig. 5.2 A,C) resulted in the 
measured functional decreases (Fig. 5.3 C). While we cannot rule out the formation 
of insoluble dimers in the lower concentration, it is possible that this result suggests 
both soluble and insoluble Aβ have a functional effect on VSMCs. Previously, 
synthetic Aβ 1-42 was shown to induce more production of its own soluble form 
and amyloid precursor protein in cultured degenerating VSMCs, but shorter Aβ 
isoforms do not [214], suggesting that the longer 1-42 isoform is primarily 
responsible for amyloidosis. This could explain the temporal drop in functional 
contractility in the intermediate concentration of 1 µM Aβ 1-42 treatment (Fig. 5.3 
C-E). These data are also consistent with Han et al., who found decreased vessel 
function even at low levels of CAA plaque formation [17]. Our observed reduction 
in Aβ-treated VSMC response to vasoactive ET-1 stimulation (Fig. 5.3 F) suggests 
a possible mechanism by which arteries are limited in their ability to dynamically 
modulate cerebral blood flow.  
Domnitz et al. found that Aβ plaques wrap around the cerebral vessels of 
transgenic mouse models, suggesting that a physical constraint limited their ability 
to vasodilate [215]. Here, we propose an alternative hypothesis: Exposure to A𝛽 
decreases the stress borne by VSMCs. As a result, the vessel remodels, primarily 
via collagen deposition. This increased collagen content stiffens the vessel, which 
decreases its mechanical dynamics, inhibiting vasodilation. We tested this 
possibility using an in vitro/in silico approach. We employed a computational model 
for cerebrovascular growth and remodeling that assumes that each VSMC has an 
ideal target stress, and growth and remodeling acts to restore this stress [9]. We 
measured decreased basal force generation in VSMCs exposed to Aβ (Fig. 5.3 C). 
Since the cell’s stress is not constrained by external loads, we took this result to 
represent a decrease in target stress. The computational model suggests that this 
decrease in target stress, coupled with compensatory collagen production, yields 
increased collagen content consistent with observations in Alzheimer’s disease 
patients [200], and can result in increased stiffness (Fig. 5.5 C) and decreased 
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vasodilation (Fig. 5.5 D), even in the absence of a loss of contractile dynamics. 
However, we also measured an Aβ-mediated decrease in ET-1-induced 
contractility (Fig. 5.3 F), suggesting that the ability of VSMCs to contract is also 
affected by Aβ. When decreased ability to contract was added to the model, we 
found an even greater decrease in vasodilation (Fig. 5.6 B). Taken together, these 
data suggest that mechano-adaptation could drive the observed change in 
vasodilation in the absence of physical restriction by plaques.  
The inability of VSMCs to respond normatively to changes in vessel 
mechanics or vasoactivation via endothelin-1-induced contraction (Fig. 5.3 F) 
could contribute to breakdown of the BBB in the intact neurovasculature [2]. Such 
a breakdown has shown to downregulate LRP-1, which is responsible for the 
physiological clearance of Aβ across the BBB [216]. A𝛽 decreases contractility in 
VSMCs (Fig. 5.3), which, in addition to reported VSMC atrophy in the vessel media 
in CAA [217], could increase the likelihood of vessel rupture [218], releasing 
neurotoxic factors into the brain parenchyma. Atrophy and loss of vasomotor 
response can both contribute to hypoperfusion, which has been shown to 
exacerbate Aβ aggregation in synapses [219] and lead to hypoxia. Recent findings 
have suggested that oxidative stress is critical in the ultimate downstream 
consequences of Alzheimer’s disease precursors: neuronal death [220, 221].  
There are some important limitations to consider in this study. Experimental 
studies were all conducted on single VSMCs, which are not perfect mimics of in 
vivo vascular tissues. The importance of cell-cell signaling, interactions with 
surrounding composite ECM, and the propagation of mechanical force throughout 
the tissue as a continuum are not captured in this work. Also, the choice of 
extracellular matrix adhesion proteins used in in vitro studies of VSMC function 
can influence VSMC phenotype [222], as well as amyloidosis [223]. Here, we used 
fibronectin as the only adhesion ECM protein, which limits the robustness of our 
study. While this is a limitation, all VSMCs were cultured in serum-free medium, 
which has been shown to promote a contractile VSMC phenotype [167], 
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superseding the reported shift in VSMCs cultured on fibronectin toward a synthetic 
phenotype [224]. Finally, the model we developed to assess the effects of VSMC 
loss of function on arterial mechanics during growth and remodeling is necessarily 
simplified compared to in vivo vessels. For example, by assuming a uniform thin-
walled vessel, we ignore the contributions of the adventitia to vessel mechanics. 
Additionally, in the total growth case, elastin increases with collagen and smooth 
muscle, though it is well-established that elastin does not functionally remodel in 
mature arteries [203]. Finally, our model only examines the endpoints of 
remodeling and does not describe the temporal evolution of vessel mechanics 
during disease progression. 
 
5.7 Conclusion 
In this study, we show that culture with Aβ induces changes in VSMC 
mechanical behavior that may be critical in the maladaptive response of cerebral 
arteries during the development of Alzheimer’s disease and other neurological 
disorders. The significance of VSMC function at the single cell level has been 
elusive amid the vast work completed in developing the amyloid hypothesis. Our 
results suggest that vascular injury mechanisms and downstream degeneration of 
neurons could be the consequence of loss of function due to biochemical 
attenuation of VSMC contractility by soluble and insoluble forms of Aβ and vessel 
remodeling to compensate for this functional loss. Further work to show the impact 
of Aβ on VSMCs in their native configuration is needed to fully understand the 
influence of Aβ in the pathology of cerebrovascular tissue. 
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Figure 5.1. Schematic of growth and remodeling in thin-walled, constrained 
mixture arterial model.  
All constituents (elastin: left, blue; collagen: middle, yellow; muscle cells: right, red) 
undergo deformation 𝑭, transitioning the artery from a reference configuration, 
𝑏(0), to a current configuration, 𝑏(𝑡). But, their zero-stress configurations evolve 
separately, yielding different elastic deformations. Zero-stress configurations are 
denoted by capital letters. Elastin and collagen are produced and degraded with 
time, with insertion at a prescribed initial stretch ratio, 𝜆𝑜
𝑒  or 𝜆𝑜
𝑐 . Deformation from 
the zero-stress configuration, 𝐵𝑒 or 𝐵𝑐, to the current configuration is denoted by 
the elastic deformation gradient tensor, 𝑭∗𝒆 or 𝑭∗𝒄. Muscle cells undergo stress-
free deformation due to growth, 𝑮, and active contraction, 𝑨. Upon reassembly and 
vessel loading, there is an elastic deformation, 𝑭∗𝒎, from the zero-stress actively 
contracted state, 𝐵𝑎
𝑚, to the current configuration, 𝑏(𝑡). 
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Figure 5.2. Treatment of VSMCs with Aβ yields differences in Aβ plaque 
formation and nuclear morphology. 
(A) Representative immunofluorescent images of single VSMCs for different 
treatment conditions; blue: DAPI-stained nuclei, green: f-actin, red: Aβ fibrils, scale 
bar: 25 µm (B) (i) Traced VSMC for Aβ plaque coverage quantification (ii) Isolation 
of VSMC area in Aβ-stained image (iii) Thresholded Aβ signal for particle analysis 
(C) Aβ plaque coverage after 24 hr of treatment; Error bars: standard deviation, *: 
significant difference, p<0.05 (D) Cell spread area after 24 hrs of Aβ treatment; 
Error bars: standard deviation (E) VSMC nuclear eccentricity after 24 hrs of Aβ 
treatment; Boxes: 25-75%, Whiskers: 10-90%, Red (thick) line: Mean, Black (thin) 
line: Median. 
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Figure 5.3. Amyloid beta influences VSMC basal functional contractility. 
(A) Representative brightfield image of VSMC on PA gel, scale bar: 100 µm (B) 
Heat map of measured substrate displacement resulting from VSMC traction (C-
E) Basal strain energy exerted by cells treated for 24 hr (C), 48 hr (D), and 96 hr 
(E) with A𝛽 1-42 (F) ET-1-induced contraction strain energy following 24 hr 
treatment with Aβ; *: significant difference, p<0.05; Boxes: 25-75%, Whiskers: 10-
90%, Red (thick) line: Mean, Black (thin) line: Median. 
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Figure 5.4. Thin-walled constrained mixture total growth model of 
cerebrovascular response to altered target stress. 
(A) Vessel wall thickness (solid line) and volume fractions of collagen (𝜙𝑐, long 
dashed line) and VSMCs (𝜙𝑚, short dashed line) (B) Circumferential growth 
stretch ratio, 𝜆𝑔𝜃 (dashed line), and radial growth stretch ratio, 𝜆𝑔𝑟 (solid line), 
relative to baseline homeostatic conditions (𝜎𝑜 = 75𝑘𝑃𝑎) (C) Pressure-radius 
curves for active (solid lines) and passive (dashed lines) mechanical responses for 
specified target stress (Red: 60 kPa, Black: 75 kPa, Blue: 90 kPa; increasing target 
stress from top left to bottom right for both active and passive curves) (D) 
Vasodilation, represented as the ratio between the passive vessel radius, rpassive, 
and the active vessel radius, ractive, as a function of target stress. 
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Figure 5.5. Thin-walled constrained mixture collagen deposition model of 
cerebrovascular response to altered target stress. 
(A) Vessel wall thickness (solid line) and volume fractions of collagen (𝜙𝑐, long 
dashed line) and VSMCs (𝜙𝑚, short dashed line) (B) Circumferential growth 
stretch ratio, 𝜆𝑔𝜃 (dashed line), and radial growth stretch ratio, 𝜆𝑔𝑟 (solid line), 
relative to baseline homeostatic conditions (𝜎𝑜 = 75𝑘𝑃𝑎) (C) Pressure-radius 
curves for active (solid lines) and passive (dashed lines) mechanical responses for 
specified target stress (Red: 60 kPa, Black: 75 kPa, Blue: 90 kPa; increasing target 
stress from top left to bottom right for both active and passive curves) (D) 
Vasodilation, represented as the ratio between the passive vessel radius, rpassive, 
and the active vessel radius, ractive, as a function of target stress. 
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Figure 5.6. Loss of VSMC ability to actively contract attenuates vasodilation 
in model vessels. 
(A) Pressure-radius curves for active (solid lines) and passive (dashed lines) 
mechanical responses for specified homeostatic active stretch ratio, 𝜆𝑎𝑜 (Red: 
0.60, Black: 0.80, Blue: 0.95; increasing 𝜆𝑎𝑜 from top left to bottom right for active 
curves, decreasing 𝜆𝑎𝑜 from top left to bottom right for passive curves), and target 
stress 𝜎𝑜 = 75 𝑘𝑃𝑎 (B) Vasodilation, represented as the ratio between the passive 
vessel radius, rpassive, and the active vessel radius, ractive, as a function of changes 
in the active stretch ratio, 𝜆𝑎𝑜, for specified target stress (Red, short dashed line: 
45 kPa, Blue, long dashed line: 60 kPa, Black, solid line: 75 kPa). 
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Chapter 6. Conclusions and Future Directions 
This work builds upon previously developed microfabrication techniques for 
measuring vascular mechanics in two ways: 1) validated improvement of an 
established technique to expand application and improve upon disease-relevance 
of temporal experiments (Chapter 3, Appendix A) and 2) use of established 
techniques to elucidate novel functional mechanics resulting from disease-
associated biochemical treatments at the single cell level (Chapters 4 and 5, 
Appendices B and C). The development and validation of genipin-modified PDMS 
substrates provides both extended culture of VSMCs on easily-characterized 
PDMS, as well as a method for maintaining patterned cell architecture. PDMS is 
also a useful substrate due to its hydrophobicity, allowing for isolation of water-
soluble biochemical factors. Our use of traction force microscopy to capture the 
loss of VSMC function in the presence of Aβ provides further support for the 
amyloid hypothesis in Alzheimer’s disease. In modeling the consequence of such 
loss of function in a thin-walled cerebral arterial model, we are able to posit that 
mechanical effects at the cellular level can yield the lost vasodilatory behavior 
observed in cerebral amyloid angiopathy [17]. These techniques and findings can 
be employed in a variety of future applications that both improve upon the current 
findings presented here and utilize the technologies developed for a variety of 
broader applications.  
 The key technique developed in this work, extended culture of patterned 
VSMCs on genipin-modified PDMS substrates, is admittedly narrow in scope at 
this point. An obvious future step in broadening the impact of this technique is to 
validate or extend it to other cell types and tissue models. Our work involved 
applying a technique proposed by Genchi et al. for culturing skeletal muscle cells 
on PDMS for up to one month [153]. Thus, skeletal muscle diseases may be a 
simple extension of the technique. Investigating mechano-adaptation in other 
chronic vascular diseases, such as hypertension, could be accomplished by 
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leveraging the elastic properties of PDMS to apply prescribed stretch to tissue 
mimics. Another intriguing application could involve probing the mechanics of 
tumor cells and metastasis over time on variable substrate stiffness or alternative 
extracellular matrix protein adsorption [225]. Modification of the microfluidic 
delivery device itself to apply a gradient of extracellular matrix could also expand 
the usefulness of genipin modification of PDMS. 
During the course of the work described here, time limitations resulted in an 
abandonment of the initial motivation, namely, the synergy between mechanics 
and biochemical perturbations in the development of CVS after bTBI. Extending 
culture on PDMS substrates now allows for a comprehensive study of 
combinatorial effects of direct mechanical insult on genipin-modified MTFs and 
subsequent exposure to heighten levels of SAH-borne factors (similar to Chapter 
4). Implementation of microfluidic patterning with the blast technique developed by 
Alford et al. [187] would allow extended observation of the phenotypic switching 
observed over the course of two days. Tissues may not maintain CVS mechanics 
over the typical disease progression of 3-7 days, which would suggest the 
importance of both blast forces and SAH factors in the severity of prolonged CVS. 
Further work to improve upon the cell viability of MTFs cultured within some form 
of isolation chamber, similar to that discussed in Appendix A, is necessary to 
properly investigate these likely synergistic effects. While our results were 
inconclusive at the single cell level regarding single SAH factor impacts on VSMC 
mechanics, the effects may prove dependent on cell-cell contacts that exist in the 
in vivo structure and that we successfully recapitulate in our MTF experimental 
model. Also, the key underlying mechanism by which SAH factors induce CVS 
mechanics may require combinatorial effects. A continued push toward high-
throughput methods, such as microfluidic delivery of small volumes of factors is 
necessary to make such experiments feasible.   
A key limitation of the TFM experiments discussed in Chapters 4 and 5 is 
that VSMCs do not exist as a sparse population in the arterial wall. While this model 
 83 
 
could be considered a mimic for an injured vessel, most progressive vascular 
diseases involve maladaptation of an intact artery. Our muscular thin film 
technology [130, 226, 227] serves as a suitable model of the highly-aligned, 
confluent VSMC structure in the arterial media. Our findings of lost VSMC function 
when treated with Aβ would be well-served by analogous experimentation with the 
MTF construct. Assessment of differences in Aβ plaque formation and size may 
prove informative regarding the mechanism in which CAA develops within the 
vessel wall. Further, utilizing our genipin-modified MTFs, we can culture arterial 
lamellae mimics and determine the longer-term effects of Aβ on the structure of 
the monolayer of cells, in addition to the functional contractility. Han et al. found 
significant disruption of VSMC alignment and confluence in CAA-model arteries in 
mice [17]. If we can recapitulate this with our experimental system, we can draw 
yet another connection between VSMC structure and/or function and the 
accumulation of Aβ, providing a more complete picture of how Aβ contributes to 
Alzheimer’s disease progression as a result of altered vascular tissue.  
 While our findings in Chapter 5 are significant, they would be greatly 
improved with a few more comprehensive studies moving forward. As referenced 
in the discussion of Chapter 5, our exclusive use of fibronectin as our cell adhesion 
extracellular matrix protein could bias VSMCs toward a synthetic phenotype [222]. 
This could also greatly influence the results discussed in Chapter 4 in our SAH-
factor assay. Future work to probe the significance of our use of fibronectin is 
desirable and could greatly improve upon current findings. One simple, yet tedious, 
step would be to repeat the TFM experiments with alternative proteins, such as 
laminin, perlecan, or collagen, and determine any differences in results. 
Additionally, Western blotting for contractile phenotypic markers such as smooth 
muscle myosin heavy chain and smoothelin in conjunction with different 
concentrations of fibronectin could further elucidate the specific phenotypic effects 
inherent in our system. However, the sparse seeding may preclude this from being 
as viable. Another key limitation of our Aβ study involves the simplicity of the thin-
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walled arterial model we developed. Given that temporal disease progression is 
the driving force for all the work contained in this dissertation, addition of temporal 
dynamics in the growth and remodeling response to lost VSMC function is of the 
utmost importance. One important consideration in this future implementation is 
how to account for and, perhaps more importantly, how to measure changes in the 
localized concentration of Aβ. Aβ aggregates are not consistent in size, so this is 
not a simple question to answer, as cells may sense higher concentrations of Aβ 
than those we prescribe experimentally.  
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Appendix A. Vasospasm-on-a-Chip: Isolation of Subarachnoid 
Hemorrhage-Associated Factors  
 
This appendix contains material based on a previously submitted research abstract 
for the 2015 Summer Biomechanics, Bioengineering, and Biotransport 
Conferences.  
 
A.1 Introduction 
Cerebral vasospasm (CVS) is a potentially lethal disease characterized by 
acute hypercontractility followed by prolonged remodeling, lumen occlusion, and 
ischemia, typically occurring 3-7 days post-injury [132]. One common precursor 
implicated in CVS development is subarachnoid hemorrhage (SAH), which results 
in the release of growth and clotting factors (e.g. PDGF, TGF-β, thrombin) in the 
subarachnoid space. These factors are thought to act on vascular smooth muscle 
contractile tone via complex biochemical pathways [74]. However, it is not clear 
which, and to what extent, individual factors (or their combinatorial effects) induce 
CVS.  
Due to the chronic nature of vascular disease, extension of culture times for 
in vitro models is desired. We developed a patterned protein deposition technique 
for extending culture of VSMCs on PDMS with genipin [130, 227]. We combined 
this microfluidic protein deposition technique for engineering vascular tissues with 
a previously developed muscular thin film (MTF) technique, allowing for chronic 
measurement of vascular contractility. Here, we add a novel isolation chamber 
device designed to allow isolated delivery of SAH-borne factors to engineered 
vascular tissues on a single chip. We employ a dose-response experimental 
strategy to investigate the critical SAH-borne factors responsible for pathological 
CVS vascular mechanics. 
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A.2 Methods 
A.2.1 Tissue Fabrication and Isolation 
Photolithographic techniques were used to fabricate microfluidic protein 
deposition devices with alternating lines of 10-µm width with 10-µm pitch in two 
rows of five blocks of 2-mm width and 4-mm length to yield a 2x5 array of 
engineered arterial lamella (Fig. A.1 A). Genipin (5 mg/ml) and fibronectin (50 
µg/ml) were sequentially drawn through the devices applied to glass cover slips 
coated in Sylgard 184 PDMS as in Chapter 3. Microfluidic devices were removed 
and acrylic isolation chamber devices were placed on the patterned substrates. 
These devices were fabricated prior to experimentation using a laser cutter, 
yielding a single array of reservoirs of 2-mm width, 10-mm length, and 6-mm height 
(Fig. A.1 B). Human umbilical artery VSMCs were then seeded into each isolation 
chamber at a cell seeding density of 80,000 cells/cm2. After 24h, confluent, aligned 
arterial lamellae mimics formed within each chamber (Fig. A.1 B) and were then 
treated with serum-free medium to induce a contractile phenotype [167]. After 24h 
in serum-free medium, each chamber was treated with one of five solutions: control 
(serum-free medium), 10-12 M, 10-11 M, 10-10 M, and 10-9 M TGF-β1 (or other SAH 
factor of interest) in serum-free medium (Fig. A.1 B, Factor Concentration). To 
simplify handling of samples and improve maintenance of isolation chamber seal, 
four chips were fabricated in a single acrylic clamping system (Fig. A.1 C). Dose-
response treatment solutions were refreshed every 24h for up to seven days of 
treatment. 
 
A.2.2 Stress Measurement  
 Contraction of independently-treated microtissues was measured using a 
previously developed MTF model [160]. At a treatment time point of interest, each 
of five tissues on a single chip was cut and released via the dissolution of poly(N-
iso-propylacrylamide) below 32°C to form a single MTF (Fig. A.2 A). Stress 
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generation in the cell layer causes the released MTF to curl. The radius of 
curvature can be used to calculate contractile stress, as in [160]. We determine 
two important stresses: 1) induced contractility via stimulation with the 
vasoconstrictor endothelin-1 (ET-1) and 2) basal tone via tissue relaxation with 
HA-1077, a rho-kinase inhibitor. 
 
A.3 Results 
Functional output for all treatments were simultaneously measured (Fig. 
A.2) for up to seven days of treatment. At 24h treatment, we found increasing raw 
stress values with increasing TGF-β concentration (Fig. A.2 B). We found a 4-fold 
increase in both normalized basal tone and normalized ET-1-induced contractility 
in tissues treated with 10-11 and 10-10 M TGF-β (Fig. A.2 C, D). Tissues cultured in 
the acrylic isolation chambers started to deteriorate after 48h (Fig. A.3), eventually 
all leading to complete delamination by 120h. All treatment levels and controls 
resulted in a similar pattern of deterioration, starting in the middle of the isolation 
chamber. Small strips of tissue remained for longer periods along the wall edges, 
as well as the branched portion of the microfluidic patterning at either end of the 
chamber (not shown).  
 
A.4 Discussion 
Here, we present an in vitro assay for isolated treatment and measurement 
of microtissue stress generation over CVS-relevant time course. Our design allows 
dose-response experimentation with other water-soluble SAH-borne factors of 
interest. Investigation of the effects of PDGF and thrombin, in addition to results 
for TGF-β (Fig. A.2), provides a platform to investigate the direct effect of these 
factors on vascular mechanics. We can employ a factorial experimental design to 
determine factor-level combinations that induce acute hyper-contractility followed 
by a shift to a synthetic remodeling VSM phenotype experiment. We will use this 
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design to assess the relative importance of these SAH-borne factors, both 
individually and in combination, yielding further understanding of the underlying 
disease mechanisms and possibly illuminating desirable treatment strategies to 
combat the pathological vascular mechanical response in CVS. Further, the ability 
to recapitulate CVS progression in an on-a-chip system may allow future 
development of our technique as a pharmaceutical assay. 
Another key feature of our design is our ability to conduct experiments over 
disease-relevant time courses. Previous microcontact printing methods for 
engineering arterial lamella showed loss of tissue integrity as early as four days in 
culture [130]. We can now perform these assays up to seven days by utilizing 
genipin to extend culture of VSMCs [130, 227]. However, our current isolation 
chamber design results in an attenuation of this improved temporal viability. There 
are two likely causes for this deleterious result: 1) leaching of cytotoxic material 
from acrylic isolation chamber devices or 2) diffusion-limited delivery of oxygen or 
convection-limited delivery of nutrients within the media. A variety of acrylic 
monomers have been implicated in reduced contraction of heart muscle in rabbits 
[228], as well as differential effects (strong vs. weak) on viability and malformation 
of rat fetuses [229]. The melting of our acrylic devices during laser cutting could 
result in the formation of cytotoxic residues that leach into the culture medium filling 
the device. Oxygen transfer may be affected with our device geometry. Previous 
work has shown the importance of oxygen transfer rate, which is dependent on 
gaseous diffusion from the head space of the culture medium [230]. While these 
possibilities seem most likely, both seem to be counterintuitive explanations for our 
observed maintenance of cell attachment at the edges of the device. Future work 
to investigate the diffusion limits of the device is necessary to determine necessary 
design modifications to allow for dose-response studies of vascular mechanics 
over disease-relevant time courses. 
  
 105 
 
 
Figure A.1. Schematic of vasospasm-on-a-chip (VOAC) model. 
(A) Photolithographic mask design for 10x10 µm channel tissue pattern and 
resulting microfluidic device. (B) Schematic representation of isolation chamber 
device application to patterned tissues yielding VOAC with increasing factor 
concentration applied from left to right. (C) Clamping assembly for concurrent 
culture of four VOAC systems. 
  
C B A 
 106 
 
 
Figure A.2. SAH-associated TGF-beta increases vascular contractility. 
(A) Brightfield images of released MTFs on a single, VOAC construct (increasing 
TGF-β concentration from left to right); Scale Bar: 1 mm. (B) Representative 
functional contractility assay and characteristic stress curve. (C) Endothelin-1-
induced contraction increases with increased concentration of TGF-β (Mean ± 
Standard Error). (D) Basal tone increases with increased concentration of TGF-β 
(Mean ± Standard Error). Stress normalized to control values (fold increases). 
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Figure A.3. Culture in isolation chamber device results in delamination 
between 24h and 48h in serum-starved medium. 
Note: VSMCs are lost in the middle of the reservoir, but remain attached and viable 
at edges. 
  
 108 
 
Appendix B. Parameter Study for Thin-Walled Cerebral Arterial 
Model   
 
This appendix contains related material not included in an invited original research 
article in press at JBME. Hald ES, Timm CD, and Alford PW. In Press. Amyloid 
Beta Influences Vascular Smooth Muscle Contractility and Mechano-Adaptation. 
In Press.  
 
B.1 Summary 
In developing our thin-walled cerebral arterial model in Chapter 5, we 
assumed specific values for our material parameters. Some parameters were 
chosen to match literature values, while others were estimated. To investigate the 
effect each of these material parameters has on the mechanics of our model artery 
at homeostasis, we performed parameter studies at a homeostatic target stress of 
75 kPa. We generated pressure-radius curves similar to those reported in Figs. 
5.4C, 5.5C, and 5.6A. The material parameters directly influence the strain energy 
density equations for each of the arterial constituents (Eqs. 5.11-5.13 and rewritten 
here as Eqs. B.1-B.3).  
For elastin, the strain energy density function is  
𝑊𝑒 =
𝐶𝑒
2
(𝜆𝜃
∗𝑒2 + 𝜆𝑧
∗𝑒2 + 𝜆𝜃
∗𝑒−2𝜆𝑧
∗𝑒−2 − 3) (Eq. B.1) 
where 𝐶𝑒 is the elastin material parameter, taken to be 24.91 kPa based on Cheng 
et al. [174] for all model outputs described in Chapter 5. Since elastin does not 
significantly remodel post-birth [203], we assumed that the elastin in the model 
was at a mature homeostatic stretch 𝜆𝑜
𝑒  in the loaded configuration so that 𝜆𝜃
∗𝑒 =
𝜆𝑧
∗𝑒 = 𝜆𝑜
𝑒 . In all model outputs described in Chapter 5, we let 𝜆𝑜
𝑒 = 1.1. 
For collagen, the strain energy density function is  
𝑊𝑐 = ∑
𝐶𝑐
𝛽
(𝑒𝛽(𝐼4
∗𝑘−1)
2
− 1)2𝑘=1  (Eq. B.2) 
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where 𝐶𝑐 and 𝛽 are collagen material parameters taken to be 42.32 kPa and 0.08, 
respectively, based on Cheng et al. [174] for all model outputs described in 
Chapter 5. 𝐼4 is the 4
th strain invariant given by 𝐼4
∗ = 𝐶𝜃𝜃
∗ cos2(𝛼𝑘) +
2𝐶𝜃𝑧
∗ sin(𝛼𝑘) cos(𝛼𝑘) + 𝐶𝑧𝑧
∗ sin2(𝛼𝑘), where 𝐶𝑖𝑗
∗  is the 𝑖, 𝑗 component of the elastic 
right Cauchy-Green tensor, defined as 𝑪∗ = 𝑭∗𝑻 ∙ 𝑭∗, and 𝛼 is the angle of the 
collagen fibers with respect to the undeformed circumferential orientation. 
Humphrey and Rajagopal proposed that when collagen turns over, old fibers are 
replaced by new fibers at a preferred stretch ratio 𝜆𝑜
𝑐  [201]. Here, we assume that 
the vessel is at homeostasis and has been for some time, so that 𝜆𝑖
∗𝑐 = 𝜆𝑜
𝑐  for all 
fibers in the loaded configuration, and we let 𝜆𝑜
𝑐 = 1.2 for all model outputs 
described in Chapter 5. 
For smooth muscle, the strain energy density is 
𝑊𝑚 =
𝐶𝑚
2
(𝐼1
∗ − 3) +
𝐴𝑚
2
(𝜆𝜃
∗𝑚 − 1)2 (Eq. B.3) 
where 𝐶𝑚 and 𝐴𝑚 are the passive and active material parameters taken to be 10 
kPa and 100 kPa, respectively, for all model outputs described in Chapter 5. 𝐼1
∗ is 
the first strain invariant with respect to the zero-stress configuration, given by 𝐼1
∗ =
𝜆𝑟
∗𝑚 2 + 𝜆𝜃
∗𝑚 2 + 𝜆𝑧
∗𝑚 2. Muscle acts to adapt the vessel quickly to changes in its 
mechanics via contraction, but to do so, it must maintain a homeostatic partially-
contracted state described by the stress-free cell shortening 𝜆𝑎𝑜 [9]. In all models, 
we assumed that the loaded active artery is at this homeostasis, and VSMC 
contractile cytoskeletons are primarily oriented circumferentially, so that 𝑨 =
𝑑𝑖𝑎𝑔[1, 𝜆𝑎𝑜 , 1], where 𝜆𝑎𝑜 = 0.8. VSMCs can also grow via hypertrophy or 
proliferation to alter their stress. Though axial growth and remodeling plays an 
important role in vessel mechanics [73, 205, 206], here, we ignored its effect and 
only included radial growth (thickening) 𝜆𝑔𝑟 and circumferential growth 𝜆𝑔𝜃. Thus, 
the growth tensor is given by 𝑮 = 𝑑𝑖𝑎𝑔[𝜆𝑔𝑟 , 𝜆𝑔𝜃, 1]. 
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First, we considered the extracellular matrix material parameters used in 
the model, 𝐶𝑒 , 𝐶𝑐 , and 𝛽. These parameters influence Eqs. B.1 and B.2. Pressure-
radius curves for the study of the elastin material parameter 𝐶𝑒 show minimal effect 
on the mechanics of our model artery (Fig. B.1 A). In studying the two collagen 
material parameters 𝐶𝑐 and 𝛽, we found increased stiffness in the modeled artery 
as we increased both parameters, with a more pronounced increase when we 
increased the exponential collagen material parameter 𝛽 (Fig. B.1 B,C). These 
studies yielded expected outcomes, as the elastin plays a minimal role in the 
mechanical response of the artery to loading. The increase in the collagen material 
parameters corresponds with increased stiffness of the material, which manifests 
in the stiffer mechanical behavior observed at the tissue level in both the active 
and the passive responses to loading. 
 Next, we considered the effects of the homeostatic stretch ratios 𝜆𝑜
𝑒  and 𝜆𝑜
𝑐   
for elastin and collagen fibers, respectively. While changing 𝜆𝑜
𝑒 , we found minimal 
effect on vessel stiffness (Fig. B.2 A). For increasing 𝜆𝑜
𝑐 , we observed 
corresponding increases in vessel stiffness (Fig. B.2 B), similar to those observed 
for increases in 𝛽 (Fig. B.1 C). This is an expected outcome, as increases in 𝜆𝑜
𝑐  
also result in increased magnitude of the exponential term in Equation B.2, leading 
to stiffer behavior by the vessel for both active and passive contributions. 
 Finally, we considered the effects of the passive and active smooth muscle 
material parameters 𝐶𝑚 and 𝐴𝑚, respectively. Significantly increasing the passive 
smooth muscle material parameter 𝐶𝑚 results in pronounced increase in the 
stiffness of the model vessel (Fig. B.3 A). The separation in the active and passive 
mechanical response is also slightly decreased as 𝐶𝑚 is increased, suggesting a 
larger contribution of the passive mechanics to the overall increased stiffness of 
the vessel. This is an expected result due to the increased dominance of the neo-
Hookean passive term in Equation B.3 as 𝐶𝑚 is increased. In the study of the active 
smooth muscle material parameter 𝐴𝑚, we found slightly increased stiffness in the 
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active behavior of the vessel with minimal response in the passive behavior (Fig. 
B.3 B).  
Taken together, these parameter studies suggest that the passive behavior 
is critically affected by effective increases in constituent stiffness, specifically for 
collagen and smooth muscle, as modulated by changing material parameters. In 
these cases, the active response is also changed, resulting in a stiffer mechanical 
response to arterial loading. The active response of the smooth muscle shows less 
direct influence due to associated parameter manipulation. This suggests that our 
model is not as susceptible to altered mechanics due to changes in material 
parameters that directly affect the active contractile response of the vessel, similar 
to the limited effects of changes in elastin properties. 
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Figure B.1. Parameter studies of elastin and collagen material parameters  
(A) Pressure-radius curves for active (solid lines) and passive (dashed lines) 
mechanical responses for modulated value of the elastin material parameter 𝐶𝑒 in 
Eq. B.1 (Red: 10 kPa, Black: 24.91 kPa [value for Chapter 5 model outputs], Blue: 
40 kPa; decreasing value for 𝐶𝑒 from top left to bottom right for both active and 
passive curves). (B) Pressure-radius curves for active (solid lines) and passive 
(dashed lines) mechanical responses for modulated value of the linear collagen 
material parameter 𝐶𝑐 in Eq. B.2 (Red: 42.32 kPa [value for Chapter 5 model 
outputs], Black: 60 kPa, Blue: 80 kPa; decreasing value for 𝐶𝑐 from top left to 
bottom right for both active and passive curves). (C) Pressure-radius curves for 
active (solid lines) and passive (dashed lines) mechanical responses for 
modulated value of the exponential collagen material parameter 𝛽 in Eq. B.2 (Red: 
0.01, Black: 0.08 [value for Chapter 5 model outputs], Blue: 0.20, Green: 0.90; 
decreasing value for 𝛽 from top left to bottom right for both active and passive 
curves). 
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Figure B.2. Parameter studies of elastin and collagen homeostatic stretch 
ratios 
(A) Pressure-radius curves for active (solid lines) and passive (dashed lines) 
mechanical responses for modulated value of the elastin homeostatic stretch ratio 
𝜆𝑜
𝑒  in Eq. B.1 according to the relation 𝜆𝜃
∗𝑒 = 𝜆𝑧
∗𝑒 = 𝜆𝑜
𝑒  (Red: 1.05, Black: 1.1 [value 
for Chapter 5 model outputs], Blue: 1.3, Green: 1.5; increasing value for 𝜆𝑜
𝑒  from 
top left to bottom right for both active and passive curves). (B) Pressure-radius 
curves for active (solid lines) and passive (dashed lines) mechanical responses for 
modulated value of the collagen homeostatic stretch ratio 𝜆𝑜
𝑐 , a component of the 
4th strain invariant 𝐼4 in Eq. B.2 (Red: 1.15, Black: 1.2 [value for Chapter 5 model 
outputs], Blue: 1.3, Green: 1.5; decreasing value for 𝜆𝑜
𝑐  from top left to bottom right 
for both active and passive curves).  
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Figure B.3. Parameter studies of the passive and active smooth muscle 
material parameters 
(A) Pressure-radius curves for active (solid lines) and passive (dashed lines) 
mechanical responses for modulated value of the passive neo-Hookean smooth 
muscle material parameter 𝐶𝑚 in Eq. B.3 (Red: 5 kPa, Black: 10 kPa [value for 
Chapter 5 model outputs], Blue: 50 kPa, Green: 90 kPa; decreasing value for 𝐶𝑚 
from top left to bottom right for both active and passive curves). (B) Pressure-
radius curves for active (solid lines) and passive (dashed lines) mechanical 
responses for modulated value of the active smooth muscle material parameter 
𝐴𝑚 in Eq. B.3 (Red: 50 kPa, Black: 100 kPa [value for Chapter 5 model outputs], 
Blue: 125 kPa, Green: 175 kPa; decreasing value for 𝐴𝑚 from top left to bottom 
right for both active and passive curves).   
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Appendix C. Influence of Co-treatment with Alpha Synuclein and 
Amyloid Beta on Vascular Smooth Muscle Function  
 
This appendix contains related material not included in an invited original research 
article at JBME. Some material included for comparative purposes is modified from 
the material under review and is reproduced with permission. Hald ES, Timm CD, 
and Alford PW. In Press. Amyloid Beta Influences Vascular Smooth Muscle 
Contractility and Mechano-Adaptation.  
 
C.1 Summary 
In addition to the amyloid hypothesis in Alzheimer’s disease progression, 
studies of other neurodegenerative diseases, such as Parkinson’s disease, have 
suggested there are overlapping effects of disease mechanisms and their impacts 
on Aβ accumulation. Alpha-synuclein, the hallmark protein implicated in 
Parkinson’s disease, coincidentally accumulates with Aβ plaque formation in over 
50% of Alzheimer’s cases [231]. Bachhuber et al. found α-synuclein inhibits Aβ 
plaque formation both in vivo and in vitro, with ~30% inhibition in vitro [209]. We 
investigated the possible impact of α-synuclein/Aβ co-exposure in vascular tissue 
and on Aβ plaque formation by treating VSMCs with a combination of 10 µM Aβ 
(Tocris Bioscience) and 1 µM α-synuclein (rPeptide), but found no inhibition of Aβ 
plaque coverage of VSMCs (Fig. C.1 A,B). We found a non-significant increasing 
trend in nuclear eccentricity as Aβ treatment concentration increased, but a 
significant increase in VSMCs treated with a combination of Aβ and α-synuclein 
(Fig. C.1 C). Treatment with α-synuclein alone resulted in no change in basal strain 
energy (Fig. C.2 A). Co-treatment resulted in a significant decrease of basal 
vascular contractility, consistent with Aβ treatment alone (Fig. C.2 A). Interestingly, 
there appeared to be some recovery of vasoactive function in VSMCs co-treated 
with Aβ and α-synuclein (Fig. C.2 B). 
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Overlaps in neurodegenerative disease pathologies are common and can 
lead to exacerbated effects [231, 232]. Bertrand et al. showed increased severity 
of CAA in cases displaying a possible coexistence of Alzheimer’s and Parkinson’s 
disease (presence of both Aβ and α-synuclein) [232]. Bachhuber et al. showed that 
coaggregation of Aβ and α-synuclein resulted in reduced Aβ plaque formation in 
vitro and in the Lewy bodies of Parkinson’s rat brain tissue [209]. We did not see 
this attenuation of plaque formation in our in vitro VSMC cultures (Fig. C.1 A,B). 
We also observed a decrease in VSMC basal tone in cells treated with a 
combination of Aβ and α-synuclein (Fig. C.2 A). These conflicting results suggest 
that the location of co-localization of α-synuclein and Aβ may have different 
outcomes. Specifically, co-localization in the arteries may have limited effect on Aβ 
plaque formation and influence on VSMC function, whereas coaggregation in 
neurons leads to reduced Aβ accumulation as observed in [209]. Our results may 
explain why an increase in CAA severity is observed in cases of overlapping 
Alzheimer’s and Parkinson’s pathologies. 
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Figure C.1. Co-treatment of VSMCs with Aβ and α-synuclein does not 
attenuate plaque formation. 
(A) Representative immunofluorescent images of single VSMCs for different 
treatment conditions. Blue: DAPI-stained nuclei, Green: f-action, Red: AB2286-
stained Aβ fibrils, Scale Bar: 25 µm. (B) Aβ plaque coverage significantly increases 
in higher concentrated treatment. Alpha-synuclein does not attenuate Aβ plaque 
formation. (C) Co-treatment with Aβ and α-synuclein results in significantly 
increased nuclear eccentricity. *: significant difference, p<0.05. 
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Figure C.2. Effects of Aβ/α-synuclein co-treatment on VSMC functional 
contractility. 
(A) Co-treatment with Aβ/α-synuclein further exacerbates reduction in VSMC basal 
function. Alpha-synuclein alone has no impact on basal function. (B) Vasoactive 
response to ET-1 induced contraction is re-gained in VSMCs co-treated with Aβ/α-
synuclein. *: significant difference, p<0.05. 
 
